An Algorithm for the Treatment of Schizophrenia in the Correctional Setting: The Forensic Algorithm Project

Charles A. Buscema, M.D.; Qamar A. Abbasi, M.D., Ph.D.; David J. Barry, M.S.; and Timothy H. Lauve, M.A.

The Forensic Algorithm Project (FAP) was born of the need for a holistic approach in the treatment of the inmate with schizophrenia. Schizophrenia was chosen as the first entity to be addressed by the algorithm because of its refractory nature and high rate of recidivism in the correctional setting. Schizophrenia is regarded as a spectrum disorder, with symptom clusters and behaviors ranging from positive to negative symptoms to neurocognitive dysfunction and affective instability. Furthermore, the clinical picture is clouded by Axis II symptomatology (particularly prominent in the inmate population), comorbid Axis I disorders, and organicity.

Four subgroups of schizophrenia were created to coincide with common clinical presentations in the forensic inpatient facility and also to parallel 4 tracks of intervention, consisting of pharmacologic management and programming recommendations. The algorithm begins with any antipsychotic medication and proceeds to atypical neuroleptic usage, augmentation with other psychotropic agents, and, finally, the use of clozapine as the common pathway for refractory schizophrenia. Outcome measurement of pharmacologic intervention is assessed every 6 weeks through the use of a 4-item subscale, specific for each forensic subgroup. A "floating threshold" of 40% symptom severity reduction on Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale items over a 6-week period is considered an indication for neuroleptic continuation. The forensic algorithm differs from other clinical practice guidelines in that specific programming in certain prison environments is stipulated. Finally, a social commentary on the importance of state-of-the-art psychiatric treatment for all members of society is woven into the clinical tapestry of this article.

(J Clin Psychiatry 2000;61:767–783)

e have entered an era of high-quality treatment for all members of society, whether it be professionals in private managed-care organizations or inmates who receive treatment in the public health sector. The seriously and persistently mentally ill population has moved into the prisons, where treatment often determines an inmate's condition at the time of release back into the community. The average length of incarceration for a convicted felon in New York State is $5^{1/2}$ years.¹ There are approximately 7700 inmates on the psychiatric rosters at any given time, and 3 times that number who refuse treatment. Thus, since deinstitutionalization changed the architecture of treatment 25 years ago, many thousands of inmates have been treated in the correctional setting and subsequently released back into the community. It has been well documented that recidivism rates for the seriously and persistently mentally ill population are quite high. In New York, an assisted outpatient treatment program was initiated in November 1999 (commonly known as Kendra's Law) to precisely track and treat these individuals following their release from prisons, prison hospitals, and civil facilities.²

The necessity for a high standard of psychiatric care, based on a common blueprint of treatment that would govern a holistic approach for the inmate-patient, seems paramount. Schizophrenia has long been regarded as one of the most refractory of all psychiatric disorders, and it is certainly one of the most challenging from the perspective of treatment in the prison setting. The logistics and standard of such treatment are presently being monitored at the Attica Correctional Facility by the federal court system as a result of the legislation known as Eng v. Goord (formerly Eng vs. Coughlin et al.).³ Questions have arisen regarding the ability to provide humane and effective psychiatric treatment to schizophrenic inmates housed in the Attica Special Housing Unit (SHU), owing to the restrictions placed on psychiatric evaluation, pharmacologic intervention, and programming.^{4,5}

Thus, in introducing what would appear to be the first forensic/correctional treatment algorithm, the focus became inmates diagnosed with schizophrenia and the methodology of such interventions, both in prison hospital (inpatient) and in prison-based satellite unit (outpatient) settings.⁶⁷

Received March 15, 2000; accepted July 12, 2000. From the Central New York Psychiatric Center (all authors), and SUNY Upstate Medical University (Dr. Buscema), Marcy, N.Y.

The authors acknowledge Hal Smith, C.S.W.; Don Sawyer, Ph.D.; Robert Hill, Ph.D.; Bethany Bowie, B.A. (research and editing); and Donna Buscema, B.A. (research and editing) for their contributions to this article.

Reprint requests to: Charles A. Buscema, M.D., Box 300, River Rd., Marcy, NY 13403 (e-mail: cnmdcab@omh.state.ny.us).

Table 1. Characteristics of the Forensic Algorithm Project That Differentiate It From Clinical Practice Guidelines

Avoidance of medications associated with physiologic dependence Potential pharmacoaugmentation after 6 weeks of monotherapy Division into 4 forensic subgroups of schizophrenia

- Rapid titration of psychotropic medications for control of agitated patients
- Division of programming into 4 distinct "tracks," which mirror the 4 forensic subgroups

Recognition of comorbidity (eg, brain injury, posttraumatic stress disorder)

Inclusion of a noncompliance algorithm

Outcome management of data generated from forensic algorithm First algorithm that accounts for prison environment as a variable in treatment

HISTORICAL PERSPECTIVE

There has been a great deal of recent effort devoted to establishing clinical practice guidelines for all psychiatric illnesses, among them schizophrenia. The most notable clinical practice guidelines have been authored by the American Psychiatric Association,⁸ the Patient Outcomes Research Team,⁹ the Expert Consensus Guidelines group,¹⁰ and most recently, the Texas Medication Algorithm Project.¹¹ In January of 1999, the New York State Office of Mental Health (OMH) introduced its own clinical practice guidelines project in 11 pilot facilities across the state (M. Finnerty, M.D., M. McLaughlin, Ph.D., unpublished guidelines, 1999).

In working with OMH Practice Guidelines, it was evident that the huge differences between the civil and correctional populations would necessitate a radically different approach.

Table 1 illustrates the differences between clinical practice guidelines for the civil population and the forensic algorithm developed under the Forensic Algorithm Project (FAP).

CORRECTIONAL FACILITY SERVICES/ENVIRONMENT

The prison environment, from the vantage of the correctional/forensic algorithm, is divided into the general population, the residential crisis treatment programs (RCTPs), intermediate care programs (ICPs), SHUs, and the proposed ICP-SHU (Table 2 provides definitions and functional descriptions).

The SHU is the location in which inmates who are behaviorally disruptive are confined for disciplinary reasons. There are many theories regarding so-called "toxic SHU syndromes," but it is clear that seriously and persistently mentally ill inmates do not function well in the SHU environment and decompensate clinically, requiring transfer to an RCTP and eventually the inpatient hospital.⁵

The proposed ICP-SHU would be a unit for behaviorally disruptive inmates with confirmed psychiatric illness.

 Table 2. Definition of Correctional Services and Programs

Service/Program	Definition
RCTP	Residential Crisis Treatment Programs have crisis beds in mental health units for individuals requiring crisis services; frequently used prior to hospitalization
ICP	Intermediate Care Programs are similar to day treatment centers but also provide segregated housing; units are staffed by both mental health and corrections staff
SHU	Special Housing Units are disciplinary cells used by corrections for behaviorally disruptive inmates; there is no programming, and inmates are in cells 23 hours per day, 7 days per week
ICP-SHU	A proposed unit for patients with persistent and/or severe Axis I disorders who also have disciplinary and behavioral problems; units will have a combination of ICP programming (4–6 hours/day) and SHU disciplinary restrictions

Programming would occur for 4 to 6 hours a day, and access to psychiatric services and pharmacologic intervention would reduce the need for inpatient hospitalization.

OMH CLINICAL PRACTICE GUIDELINES PROJECT ALGORITHM

Figure 1 is a schematic of the original OMH Algorithm (Clinical Practice Guidelines Project), which was developed by several researchers including Molly Finnerty, M.D., and Mederick McLaughlin, Ph.D. (unpublished guidelines, 1999). The Brief Psychiatric Rating Scale (BPRS)¹² was selected as the principal instrument of outcome measurement. An automated prescribing summary (Figure 2) would give the clinician a 10-year perspective of the success or failure of pharmacologic interventions and would presumably govern neuroleptic decision making (M. Finnerty, M.D., M. McLaughlin, Ph.D., unpublished guidelines, 1999).

THE FORENSIC ALGORITHM

The FAP format establishes critical decision points in a longitudinal manner, beginning at 6 weeks and extending throughout the course of treatment for 1 year (Figure 1); reference 11 and M. Finnerty, M.D., M. McLaughlin, Ph.D., unpublished guidelines, 1999). Both pharmacologic and nonpharmacologic interventions would continue, based on the same FAP blueprint, in the outpatient satellite unit following discharge.

The patient is begun on any antipsychotic medication except clozapine on admission to the prison hospital on the basis of clinical presentation. Thus, the first neuroleptic may be a conventional or an atypical agent. At the time of admission, and once a week for the first 6 weeks of inpatient stay, a physician administers the BPRS.¹² The Global Assessment of Functioning (GAF)¹³ is also administered at admission. BPRS scores are plotted on a graph for each




Figure 1. Overview of the New York State Office of Mental Health Algorithm^a

Figure 2. Automated	Prescribing	Summary ^a

Medication	Ordering Physician	Dates Medicat			ratior dicat			inimu Dose ^l			aximı Dose		
		Start	Stop	< R	R	>R	< R	R	>R	< R	R	>R	
Antipsychotics	5												
		Y O											
		(2	0	_								
		Ň	J	D.		X							
Mood Stabilize	ers	· · ·											
				2	>,	Q	0_						
					Ó	0	1						
					~	D	0	ア					
Antidepressan	nts	·											
							1	2	Y				
								Q		0	×		
											0		
Anxiolytics													
													_
													-0
													n:
		· · · · · ·										·	
from M. Finn	erty, M.D., M.	McLaughli	n. Ph.C)	nubl	ished	guid	leline	-s 10	999	Abbr	eviatio	n:

^bA mi ^cA maximum dose trial sustained for fewer than 6 weeks is denoted by "n/t."

week; the threshold of improvement that would warrant continuation of the original neuroleptic medication is set at 40% of the admission BPRS score (Figure 3). There is substantiative evidence in the clinical literature for use of a 40% reduction in symptom severity as measured by BPRS scores as an acceptable threshold of improvement.¹⁴ Most clinically based studies utilize reduction in symptom severity as a measure of positive clinical outcome. The BPRS is the most widely used instrument for determination of clinical improvement in schizophrenia.

The first critical decision point in the algorithm occurs at 6 weeks. At this time, the patient is administered the Positive and Negative Syndrome Scale (PANSS)¹⁵⁻¹⁸ and assigned to 1 of 4 forensic subgroups on the basis of the highest score of the sum of the 4 items (BPRS or BPRS/ PANSS) constituting each of the 4 forensic subgroups.

Staf Signature Staf Title Date Completed Staf Signature WD Date Completed Staf Signature Careet (SAF Highest (MF signature Staf Signature 10. Analety International Work Patient Incompletational Withdawsid 11. Hostility Point Forme Incompletation 12. Somatic Concerns Search his SPRS ID Number Staf Signature Incompletation 13. Guil Feelings Search his SPRS ID Number Staf Signature Incompletation prove Incompletation prove Search his SPRS ID Number Staf Signature Incompletation prove Incompletation prove Search his SPRS ID Number Staf Signature Incompletation prove Incompletation prove Search his SPRS ID Number Staf Signature Incompletation prover Incompletation prover <t< th=""><th>Swith A. HD 12/09/2000 Just Th Patient Dison 10 Current GAF Highest GAF is Last Yrea Just Th Patient GE 10 9999999 25 40 Just Th Patient GE 10 9999999 25 40 Just Th Patient GE 10 1 Uncooperativements 10. Artsiety Just Th Patient GE 10 1 Uncooperativements 10. Artsiety Just Th Patient GE 10 1 Uncooperativements 11. Hostility Point X C C C C C 2 Encotocnall Withduesd 11. Hostility Point X C C C C C 3 Motas Ristandation 12. Sonatic Concerns Search for SPRS ID Number Search for SPRS ID Number 4 Terrate Porte Post Search for SPRS ID Number Search for SPRS ID Number 5 Marratises Post Supponenters Post Supponenters Search for SPRS ID Number 6 Elibrated Affect 15 Supponenters Search for SPRS ID Number 7 Exclosement Teochrately servere</th><th>Swith A. WD W2/05/200 Image: Itality Press Dison ID Current BAF Highest BAF is Last Ynee Image: Dison Press Image: Itality Press 999999 25 40 Image: Dison Press Image: Itality Press Image: Itality Press 1. Uncooperativements 10. Answerty Image: Itality Press Image: Itality Press Image: Itality Press 1. Uncooperativements 10. Answerty Image: Itality Press Image: Itality Press Image: Itality Press 1. Uncooperativements 10. Answerty Image: Itality Press Image: Itality Press Image: Itality Press 2. Encotecnel Withdumsi 11. Handlig Image: Itality Press Image: Itality Press Image: Itality Press 3. Motor Retectation 12. Somatic Concerns Image: Itality Press Image: Itality Press Image: Itality Press 4. Tensors 13. Guil Freelings Image: Itality Press Image: Itality Press Image: Itality Press 5. Marynetisms Productly torvers Image: Itality Press Image: Itality Press Image: Itality Press 6. Environ Image: Itality Press Image: Itality Press Image: Itality Press Image: Italitality Press 7. Exco</th><th>Swith A. WD W2/05/200 Image: BAF Highest BAF Highe</th><th>Sindh, A. WD Current DAF Highest DAF Ware Sindh Si</th><th>Swith A. WD W2/05/200 Image: Itality in the itality increases Image: Itality increase Image: Italitalitality increases<!--</th--><th>Elle Data Help</th><th>vez Piogress N</th><th>of at</th><th></th><th></th><th></th></th></t<>	Swith A. HD 12/09/2000 Just Th Patient Dison 10 Current GAF Highest GAF is Last Yrea Just Th Patient GE 10 9999999 25 40 Just Th Patient GE 10 9999999 25 40 Just Th Patient GE 10 1 Uncooperativements 10. Artsiety Just Th Patient GE 10 1 Uncooperativements 10. Artsiety Just Th Patient GE 10 1 Uncooperativements 11. Hostility Point X C C C C C 2 Encotocnall Withduesd 11. Hostility Point X C C C C C 3 Motas Ristandation 12. Sonatic Concerns Search for SPRS ID Number Search for SPRS ID Number 4 Terrate Porte Post Search for SPRS ID Number Search for SPRS ID Number 5 Marratises Post Supponenters Post Supponenters Search for SPRS ID Number 6 Elibrated Affect 15 Supponenters Search for SPRS ID Number 7 Exclosement Teochrately servere	Swith A. WD W2/05/200 Image: Itality Press Dison ID Current BAF Highest BAF is Last Ynee Image: Dison Press Image: Itality Press 999999 25 40 Image: Dison Press Image: Itality Press Image: Itality Press 1. Uncooperativements 10. Answerty Image: Itality Press Image: Itality Press Image: Itality Press 1. Uncooperativements 10. Answerty Image: Itality Press Image: Itality Press Image: Itality Press 1. Uncooperativements 10. Answerty Image: Itality Press Image: Itality Press Image: Itality Press 2. Encotecnel Withdumsi 11. Handlig Image: Itality Press Image: Itality Press Image: Itality Press 3. Motor Retectation 12. Somatic Concerns Image: Itality Press Image: Itality Press Image: Itality Press 4. Tensors 13. Guil Freelings Image: Itality Press Image: Itality Press Image: Itality Press 5. Marynetisms Productly torvers Image: Itality Press Image: Itality Press Image: Itality Press 6. Environ Image: Itality Press Image: Itality Press Image: Itality Press Image: Italitality Press 7. Exco	Swith A. WD W2/05/200 Image: BAF Highest BAF Highe	Sindh, A. WD Current DAF Highest DAF Ware Sindh Si	Swith A. WD W2/05/200 Image: Itality in the itality increases Image: Itality increase Image: Italitalitality increases </th <th>Elle Data Help</th> <th>vez Piogress N</th> <th>of at</th> <th></th> <th></th> <th></th>	Elle Data Help	vez Piogress N	of at			
Interest Interstity 2 Enotional Withdrawel 11. Hostily Prore Interstity 2 Molas Retactation 12. Sonatic Concerns 7 Invition Interstity 4. Tension 13. Guil Feelings Inviter Interstity 5. Mannetismon Proteining 14. Giandooty Incide allely servers Interstity servers 6. Elitarised Affect 15. Suspectmenterst Invite Interstity servers	Intervite Intervite Point 2 Enotional Withduesd 11. Hostilly Point 3 Mote Retectation 12. Sonalic Concerns Search for SPRS ID Number 3 Mote Retectation 12. Sonalic Concerns Search for SPRS ID Number 4. Tarsoon 13. Guil Finsings Increa 14. Tarsoon 13. Guil Finsings Increa 5. Marriense: Posture Increa Increa 5. Marriense: Posture Increa Increa 6. Elizated Affect 15. Surpicementers inverse Increase Increase 7. Exchangering 16. Unusual Thought Context inverse Increase Increase	Investe Investe 2. Encitional Withdussi 11. Hankilly Prove Investe 3. Motor Retactation 12. Somatic Concerns Prove Investe 3. Motor Retactation 12. Somatic Concerns Prove Investe 4. Tensor 13. Guil Tenlings Investe Investe S. Maryesister Producing 14. Giardouty Proderately servere Investe 5. Maryesister Producing 14. Giardouty Provere Investe 5. Maryesister Producing 14. Giardouty Provere Investe 6. Etherted Attect 15. Suspectatorest Provere Investe 9. Conceptual Disaganization 17. Halacinatory Behavior Proderately servere Investe	Invester Invester 2. Encotonal Withdussal 11. Hushily Prove Invester 3. Motor Retactation 12. Sonatic Concerns Prove Invester 3. Motor Retactation 12. Sonatic Concerns Prove Invester 4. Tensor 13. Guilt Feelings Invester Invester S. Marvestense Producing 14. Guardootly Incleasibly tenses Incleasably tenses 5. Marvestense 15. Suspectmaneers Prover Incleasably tenses 6. Etherted Attect 15. Suspectmaneers Prover It. Unucual Thought Content Prodecately tensee It. Unucual Thought Content	Invester Invester 2. Encotonal Withdussal 11. Hushily Prove Invester 3. Motor Retactation 12. Sonatic Concerns Prove Invester 3. Motor Retactation 12. Sonatic Concerns Prove Invester 4. Tensor 13. Guilt Feelings Invester Invester S. Marvestense Producing 14. Guardootly Incleasibly tenses Incleasably tenses 5. Marvestense 15. Suspectmaneers Prover Incleasably tenses 6. Etherted Attect 15. Suspectmaneers Prover It. Unucual Thought Content Prodecately tensee It. Unucual Thought Content	Jerenice Invester Post 2 Encional Withduesd 11. Hushilp Post Invester Invester Invester 3 Motor Retaction 12. Sonatic Concerns Search ins SPPS ID Number Forme Invester Invester Search ins SPPS ID Number A Terroom Invester Invester Search ins SPPS ID Number S Marresister Pointing Informe Search ins SPPS ID Number S Marresister Pointing Informe Search ins SPPS ID Number S Marresister Point Search ins SPPS ID Number Search ins SPPS ID Number S Marresister Point Informer Informer Search ins SPPS ID Number S Marresister Point Informer Informer Search ins SPPS ID Number S Marresister Point Informer Informer Search ins SPPS ID Number S Marresister Information Information Informer Information Proferably server Information Information Information Information Proferably server Information Information Information Information Staft Signatur	Swith A. Dikon ID	MD Current GAF	C2/05/2000 Highest GAF in Last Y	nor InPatient	CI	10
moderately severe 💌		20. 20	Weeks	Weeks The Date Date Date The Date Date	Staff Signature Staff Title Date Completed ✓ X C Hame ILast, First DBHI Smith, A. M0 W B/22/2000 W Journal to Patient DBHI DBHI Grion ID Durant GAF Highest GAF in Last Year Image ILast, First DB Image ILast, First Image ILast, Fi	Encience Withd Encience Withd Fore A Motor Retactatio Fore A Tension Inverse S Mannesisme Po Focherately servere E. Bharted Affect Fore 7. Eschement Revent B. Conceptual Diss	n n n n n n n n n n n n n n n n n n n	Invest II. Hostility Invest II. Hostility Invest II. Sonatic Concerns II. Guilt Finnings Form II. Guilt Finnings II. Guilt Finnings II. Guingecharter II. Surgecharter II. Surgecharter II. Surgecharter II. Unusual Thought Content Tooderately revens II. Halucanatory Schavios Tooderately revens II. Halucanatory Schavios	Par da la Propertie Seaschi		6 ý -
Staff Signature Staff Title Date Completed ✓ X C Smith, A. M0 W (B2/22/2000)) Items (Last, Find) DB10 Grion ID Current GAF Highest (LAF) in Last Year Insert In Patient DB 999993 GO 40 Insert In Patient DB DB 1. Uncompletativements To Ansiety Insert In Patient DB Ward 2. Enotonal Withdrawed 11. Hostility Ite Mail Ite Mail	Staff Signature Staff Title Date Completed ✓ X C Name Llast, First Diff Smith, A. M0 W (02/22/2000) Image: Line Pariset Image: Line Pariset Image: Line Line Line Line Line Line Line Line	Staff Signature Staff Title Date Completed ✓ X C Hame.ILast.Find DBH Smith.A. M0 W B2/22/2000 W Jruset in Patient Items.ILast.Find DBH Grion ID Durant GAF Highest GAF in Last Year Jruset in Patient Items.ILast.Find DBH 999993 GO 40 Wind Items.ILast.Find DBH 1. Uncompletativements To Ansiety Post DGB Wind 2. Enotonal Withdrawed 11. HostBay Post Items.ILast.Find DBH	Smith, A. MD W B/22/2000 W Grion ID Duttert GAF Highest GAF in Last Year Inset In Patient 999999 GO 40 Interest GAF Edd 1. Uncooperativements To: Ansiety End Edd 2. Enotorial Withdravel 11. Hostility Enotional Withdravel	Center Ind T Cent		Veeks Landse Oorloop Ele Data Helo Statt Signature Statt Signature Signat	Stat Tale MO Durnet GAF FO Intered	Date Completed Date Completed Highest DAF in Last Y Highest DAF in Last Y Highest DAF in Last Y 10 Areaty Field T	Feat V C Josef In Palent Josef Out Palent Boat	12 800	Dista 10 Ward
Staff Signature Staff Title Date Completed ✓ X C Smith, A. M0 W (B2/22/2000)) Items (Last, Find) DB10 Grion ID Current GAF Highest (LAF) in Last Year Insert In Patient DB 999993 GO 40 Insert In Patient DB DB 1. Uncompletativements To Ansiety Insert In Patient DB Ward 2. Enotonal Withdrawed 11. Hostility Ite Mail Ite Mail	Staff Signature Staff Title Date Completed ✓ X C Name Llast, First Diff Smith, A. M0 W (02/22/2000) Image: Line Pariset Image: Line Pariset Image: Line Line Line Line Line Line Line Line	Staff Signature Staff Title Date Completed ✓ X C Hame.ILast.Find DBH Smith.A. M0 W B2/22/2000 W Jruset in Patient Items.ILast.Find DBH Grion ID Durant GAF Highest GAF in Last Year Jruset in Patient Items.ILast.Find DBH 999993 GO 40 Wind Items.ILast.Find DBH 1. Uncompletativements To Ansiety Post DGB Wind 2. Enotonal Withdrawed 11. HostBay Post Items.ILast.Find DBH	Swith, A. MD W B/22/2000 W Grion ID Durrent GAF Highest GAF in Last Year Insect In Patient 9999939 GO 40 Insect In Patient 1. Uncooperativements 10. Ansiety moderate moderate 2. Enotorial Withdravel 11. Hostility	Center Ind T Center Ce	3. Motor Retardation 12. Servatic Concerns Tearch to BPRS ID Number	Veeks Useks	Stat Tite MO Current GAF GO ent Entered		Tear	80 802 9 X V	Dista 10 Ward
Staff Signature Staff Title Date Completed ✓ X C Smith, A. M0 W (B2/22/2000)) Items (Last, Find) DB10 Grion ID Current GAF Highest (LAF) in Last Year Insert In Patient DB 999993 GO 40 Insert In Patient DB DB 1. Uncompletativements To Ansiety Insert In Patient DB Ward 2. Enotonal Withdrawed 11. Hostility Ite Mail Ite Mail	Staff Signature Staff Title Date Completed ✓ X C Name Llast, First Diff Smith, A. M0 W (02/22/2000) Image: Line Pariset Image: Line Pariset Image: Line Line Line Line Line Line Line Line	Staff Signature Staff Title Date Completed ✓ X C Hame.ILast.Find DBH Smith.A. M0 W B2/22/2000 W Jruset in Patient Items.ILast.Find DBH Grion ID Durant GAF Highest GAF in Last Year Jruset in Patient Items.ILast.Find DBH 999993 GO 40 Wind Items.ILast.Find DBH 1. Uncompletativements To Ansiety Post DGB Wind 2. Enotonal Withdrawed 11. HostBay Post Items.ILast.Find DBH	Swith, A. MD W B/22/2000 W Grion ID Durrent GAF Highest GAF in Last Year Insect In Patient 9999939 GO 40 Insect In Patient 1. Uncooperativements 10. Ansiety moderate moderate 2. Enotorial Withdravel 11. Hostility	Center Ind T Center Ce	3. Hotor Retardation 12. Senatic Concerne Tearch to BPRS ID Namber Prone Image: Concerne Image: Concerne Image: Concerne 4. Tendon 13. Guilt Feelinge Image: Concerne Image: Concerne mid Image: Concerne Image: Concerne Image: Concerne	Veeks	Stat Tite MO Current GAF GO Encol	Cle Date Completed Date Com	Tear	80 802 9 X V	Dista 10 Ward
Staff Signature Staff Title Date Completed ✓ X C Hame Last. Find Ditter Smith.A. M0 W (B2/22/2000)) Image: Last. Find Ditter Ditt	Staff Eignature Staff Title Date Completed Immull.ast. Find Diff. Smith. A. MO Immull.ast. Find Immull.ast. Find Diff. Onion 10 Current GAF Highest BAF in Last Year Immull.ast. Find Diff. 999993 GO 40 Immull.ast. Find Diff. 999993 GO Anisety Immull.ast. Find Diff. 999993 GO Mathematication Total Pasterial Diff. 1. Uncorporativeress No. Anisety Poset Diff. moderate Immull.ast. Find Diff. Diff. 2. Encotoreal Withdrawell 11. Hostility Poset Immull.ast. Find Torre Immull.ast. Find Immull.ast. Find Immull.ast. Find Diff. 3. Mator Relation 12. Scenatic Concerner Teach to BPPS ID Number Immull.ast. Find Immull.ast. Find 4. Tension 13. Guilt Feelings Immull.ast. Find Immull.ast. Find Immull.ast. Find 13. Mator Relation Torre Immull.ast. Find Immull.ast. Find Immull.ast. Find 13. Mator Relatitition Torre I	Staff Signature Staff Title Date Completed Items.IL.ant. Find DB11 Smith. A. H0 Wig2/22/2000 Image: Image	Swith, A. M0 W W/22/2000 Image: Index. Index	Image: second withdrawel Ind Image: second withdrawel 2 Excelored Withdrawel 11. Hostiky Pone Image: second withdrawel 3 Motor Retactation 12. Senatic Concerns 7 more Image: second withdrawel 4. Tensori 12. Guilt Feelings Inid Image: second withdrawel 5. Marretistus Protect 14. Goodewidy	3 Motor Retardation 12. Servatic Concerns Terech to BPRS ID Number Prone Image: Concerns Terech to BPRS ID Number 4. Tencion 13. Guilt Feelings Init Image: Concerns 5. Mannestons, Printang 14. Grandenity	Veeks Useks Useks Useks Useks Useks Useks Useks Useks Useks Usek Usek	Staf Title MO Custeri GAF GO Interest I		Tear	80 802 9 X V	Dista 10 Ward
Staff Eignature Staff Title Date Completed Items.IL.ant. Find DB11 Smith. A. H0 Items.IL.ant. Find DB11 Orion 10 Durrert GAF Highest GAF is Last Yrear Items.IL.ant. Find DB11 999993 GO Highest GAF is Last Yrear Items.IL.ant. Find DB11 999993 GO Highest GAF is Last Yrear Items.IL.ant. Find DB11 10 Durrert GAF Highest GAF is Last Yrear Items.IL.ant. Find DB11 10 Durrert GAF Highest GAF is Last Yrear Items.IL.ant. Find DB11 11 Hoto Personal Items.IL.ant. Find DB11 Items.IL.ant. Find DB11 11 Hoto Personal Items.IL.ant. Find DB11 Items.IL.ant. Find DB11 12 Service Items.IL.ant. Find DB11 Items.IL.ant. Find DB11 13 Mator Relation Items.IL.ant. Find DB11 Items.IL.ant. Find DB11 13 Guide Service Items.IL.ant. Find Items.IL.ant. Find DD11 Items.IL.ant. Find Items.IL.ant. Find Items.IL.ant. Find Items.IL.ant. Find<	Staff Eignature Staff Title Date Completed Items.ILlest.Find Dittle Smith.A. HO Items.ILlest.Find Dittle Items.ILlest.Find Dittle Orion ID Durrent GAF Highest BAF in Last Ynar Inset In Patient Dittle Dittle 999999 GO GO Highest BAF in Last Ynar Inset In Patient Dittle Dittle 999999 GO GO Highest BAF in Last Ynar Inset In Patient Dittle Dittle 10 Durrent GAF Highest BAF in Last Ynar Inset In Patient Dittle Dittle 10 Durrent GAF Highest BAF in Last Ynar Ite and Patient Dittle Dittle 11 Honor Retardation Tit Hostility Ite and to Prove in the PRES ID Number Ite and to Presson Ite and to Presson 2 Mator Retardation Tit Guil Feelingte Ite and to Presson Te and to Presson Ite and to Presson 4 Tennion Tit Guil Feelingte Ite Starpicourrense Ite Starpicourrense 5 Haveretistes Pressure Te Starpicourrense Ite Starpicourrense 6 Blanted Affect Tit Suppicourrense	Staff Signature Staff Title Date Completed Items.IL.ant. Findl DB111 Smith. A. HD Items.IL.ant. Findl DB111 Drion ID Dursert GAF Highest GAF is Last Yrair Items.IL.ant. Findl DB111 9999993 GO Highest GAF is Last Yrair Items.IL.ant. Findl DB111 10 Dursert GAF Highest GAF is Last Yrair Items.IL.ant. Findl DB111 9999993 GO Hold Findlaws Items.IL.ant. Findl DB111 10 Dursert GAF Highest GAF is Last Yrair Items.IL.ant. Findl DB111 11 House Test In Passert Items.IL.ant. Findl DB111 12 Excolored Withdraws Ttems.IL.ant. Findl DB111 13 Hand Items.IL.ant. Findl DB111 14 Findl Items.IL.ant. Findl DB111 13 Guil Feelings Tempon Items.IL.ant. Findl DB111 14 Grandenally Items.IL.ant. Findl Items.IL.ant. Findl DB111 14 Grandenally Items.IL.ant. Findl Items.IL.ant. Findl Items.IL.ant. Findl Items.IL.	Swith, A. M0 W (B/22/2000 W) (mathin Patient) Drion 10 Datent GMF Highest GMF in Last Ynee (mathin Patient) (Mathin Patient) 10 Datent GMF Highest GMF in Last Ynee (Mathin Patient) (Mathin Patient) (Mathin Patient) 10 Datent GMF Highest GMF in Last Ynee (Mathin Patient) (Mathin Patient) (Mathin Patient) 10 Datent GMF Mathin Patient (Mathin Patient) (Mathin Patient) (Mathin Patient) 10 Uncompetativements Mathin Patient (Mathin Patient) (Mathin Patient) (Mathin Patient) 2 Ecotoonal Withdrawell 11 Hoteliky (Mathin Patient) (Mathin Patient) 3 Motor Retardation 12 Somatic Concerns Teach to (BPRG ID Namber) 7 Mathin Patient 13 Guil Feelinge Teach to (BPRG ID Namber) 14 Mathin Patient (Mathin Patient) (Mathin Patient) 6 Elsated Affeorial 15 Supprocements	Image: mode with an end mid mid mid 2. Ecotoroal Withdramit 11. Hostiky Pone mid mid 3. Motor Retardation 12. Somatic Concerns Pone mid Pone mid 4. Tendon 13. Guil Feelings mid mid 14. Grandmidy mid mid 6. Elasted Affect 15. Suppicournest	3 Motor Retardation 12. Senatic Concerne Tereth to BPRS ID Number Prone Image: Concerne Tereth to BPRS ID Number 4. Tension 13. Guilt Feelinge mid Image: Concerne 5. Harmestore: Postang 14. Grandinity mid Image: Concerne 6. Blanted Affect 15. Supposument	Inone Weeks Inclusion of the procession of the p	Staf Title MO Custert GAF GO Interest I	Date Completed Date Completed Date Completed Highest DAF in Last V Highest DAF in Last V 10. Arviety mid: 11. Hostiky mid: 12. Sonatic Concerns From 11. Guil Feelings From 11. Guil Feelings From 11. Guil Feelings From 11. Guil Feelings From 11. Supposed 11. J.	Tear	80 802 9 X V	Dista 10 Ward
Staff Eignature Staff Title Date Completed Items.ILast.Find DB10 Smith.A. H0 Items.ILast.Find DB10 Orion 10 Durant GAF Highest GAF in Last Yrear Items.ILast.Find DB10 999999 GO Highest GAF in Last Yrear Items.ILast.Find DB 10 Durant GAF Highest GAF in Last Yrear Items.ILast.Find DB 11 Uncooper difference 10 Aniety Items.ILast.Find DB 10 Durant In Passert Md Items.ILast.Find DB Ward 12 Excolored Withdrawsi 11 Hostility Items.ILast.Find DB 13 Mater Retardation 12 Senate: Concerns Tensich to BPRES ID Number Items.ILast.Find Items.IL	Staff Signature Staff Title Date Completed Immuniliant, Find Dittle Smith, A, HO Immuniliant, Find Dittle Immuniliant, Find Dittle Orion 10 Current GAF Highest GAF is Last Yner Immuniliant, Find Dittle 10 Current GAF Highest GAF is Last Yner Immuniliant, Find Dittle 10 Current GAF Highest GAF Immuniliant, Yner Immuniliant, Find Dittle 10 Current GAF Highest GAF Highest GAF Immuniliant, Find Dittle 10 Current GAF Highest GAF Highest GAF Immuniliant, Find Dittle 11 Hore Retardation Immuniliant, Find Immuniliant, Find Dittle 11 Hore Retardation 11 Hore Retardation Immuniliant, Find Dittle 12 Schult Feelinge Immuniliant, Find Immuniliant, Find Immuniliant, Find Dittle 3 Motor Retardation 12 Schult Feelinge Immuniliant, Find Immuniliant, Find Immuniliant, Find 3 Motor Retardation 12 Schult Feelinge	Staff Signature Staff Title Date Completed Immediate Completed Smith A, H0 Immediate Completed Immediate Completed Smith B Dates Completed Immediate Completed Immediate Completed Smith B Immediate Immediate Immediate Immediate 1. Uncomplete diverses India Arminity Immediate	Swith, A. M0 W (M2/22/2000 W) Just in Patient Drion 10 Darrert GAF Highest GAF in Last Yner Just in Patient Ed in 1000000000000000000000000000000000000	Indd Imid Imid 2. Excotored Withdramd 11. Hostilly Poins Indd 3. Motor Retardation 12. Scenatic Concerns Poins Indd 9. Motor Retardation 12. Scenatic Concerns Poins Indd 9. Motor Retardation 12. Scenatic Concerns Poins Index 9. Motor Retardation 12. Scenatic Concerns Poins Index 9. Tencion Index 13. Guilt Feelings Index 14. Grandeniky Index 15. Supprocurrent Index all 16. Biasted Affect 15. Supprocurrent 17. Excitancert 15. Unusual Thought Conternt	3 Motor Retardation 12. Sensitic Concerns Terech for BPRS ID Number 4. Tencion 13. Guilt Feelings Initial mid mid Initial 5. Mannestons: Postareg 14. Grandmity mid mid 6. Blanted Affect 15. Suppicourses Frome mid 7. Exclement 16. Unusual Thought Contern	Inone Weeks Internet Staff Signature Staff Signature Smith, A, Drion ID 999999 1. Uncooperativen Inone 2. Enotonal Withd Fore 3. Motor Retactate Fore 4. Temoon Inole 1. Mannesses, Pa Inole 6. Biasted Affect Fore 7. Excitement	Staf Title MO Caserd GAF FO Dated Starting Start		Internet in Patient Internet In Patient Internet Internet Rout Search 1	80 802 9 X V	Dista 10 Ward
Staff Signature Staff Title Date Completed Items.ILast.Find DBUIL Smith, A, H0 Items.ILast.Find DBUIL Items.ILast.Find DBUIL Smith, A, H0 Items.ILast.Find DBUIL Items.ILast.Find DBUIL Smith, A, H0 Items.ILast.Find DBUIL Items.ILast.Find DBUIL Smith ID Dursert GAF Highest GAF is Last Ynee Items.ILast.Find DBUIL 9999999 GO Items.ILast.Find DBUIL Items.ILast.Find DBUIL 1. Uncompletelitivement Items.ILast.Find Items.ILast.Find DBUIL Items.ILast.Find DBUIL 1. Uncompletelitivement Items.ILast.Find Items.ILast.Find DBUIL Items.ILast.Find DBUIL 1. Uncompletelitivement Items.ILast.Find Items.ILast.Find DBUIL DDB Items.ILast.Find DBUIL 2. Endotorial Items.ILast.Find Items.ILast.Find DBUIL DDB Items.ILast.Find DDB 3. Motor Retardiation 12. Senatic Concentry Foreiro Items.ILast.Find DDB Items.ILast.Find DDB	Staff Eignuture Staff Title Date Completed Item II.last.find DBLB Staff Eignuture H0 Item II.last.find DBLB Grion ID Darset GAF Highest GAF is Last Year Item II.last.find DBB 10 Darset GAF Highest GAF is Last Year Item II.last.find DBB 10 Darset GAF Highest GAF is Last Year Item II.last.find DBB 10 Darset GAF Highest GAF is Last Year Item II.last.find DBB 10 Darset GAF Highest GAF Item II.last.find DBB 11 Hossilay Item II.last.find DBB Ward 12 Enclosed Mid Item Item II.last.find DBB 3 Motor Retardation 11 Hossilay Item II.ast.find DBB 13 Marrier Form Item II.ast.find DB DB 14 Goordenaly Item II.ast.find Item II.ast.find DB 14 Goordenaly Item II.ast.find Item II.ast.find Item II.ast.find 15 Suppinter Item II.ast.find	Staff Eignuture Staff Title Date Completed Items.ILast.Find DBIII Seath.A. H0 Items.ILast.Find DBIII Grion ID Darreet GAF Highest GAF Title Items.ILast.Find DBIII 9000000 Items.ILast.Find DBIII Items.ILast.Find DBIII 10 Darreet GAF Highest GAF Title Items.ILast.Find DBIII 10 Darreet GAF Highest GAF Title Items.ILast.Find DBIII 10 Darreet GAF Highest GAF Title Items.ILast.Find DBIII 11 Highest GAF Title Last.Find DBIII Items.ILast.Find DBIII 2 Enotional Withdrawed Items.ILast.Find DBIII Items.ILast.Find DBIII 3 Motor Retardation 12 Sensitic Concerns Fourier Teauch Ite BFPRS ID Number 13 Marreetines Proteory 13 Goodewide Teauch Ite BFPRS ID Number 14 Toron 13 Goodewide Teauch Ite BFPRS ID Number 15 Segectoureres Toron Toron Teauch Iteaut Find 16	Seath, A. M0 Wild 22/2000 Instant In Patient Drion 10 Duranet GAF Highest GAF in Last Yree Instant In Patient It is in Diggs 999993 G0 G0 Animity Itel and Yree Itel and Yree Itel and Yree 1. Uncooperativement 10. Animity Mode Itel and Yree Itel and Yree Itel and Yree Index 100 Market In Patient Mid Itel and Yree Itel and Yree Itel and Yree Index 100 Market In Patient Mid Itel and Yree Itel and Yree Itel and Yree Index 100 Mid Itel and Yree Itel and Yree Itel and Yree Itel and Yree Index 100 Mid Itel and Yree Itel and Yree Itel and Yree Itel and Yree 3. More Retardation 12. Security Concerns Teach Itel BPRS ID Number Yree or id Itel and Yree 13. Marketines Protein Itel Good Affect 15. Supponduments Itel and Yree Itel and Yree 14. Good Affect 15. Supponduments Itel and Yree Itel and Yree Itel and Yree 15. Lineaned Theodin Itel and Yree Itel and Yree </td <td>Ind Image 2. Excetored Withdravel 11. Hostilly Prove mild 3. Motor Retactation 12. Senatic Concerns Torre Image 4. Tension 12. Senatic Concerns Fore Image 4. Tension 12. Guilt Feelings Inid Image Image Image S. Mannestons 14. Goordinally Image Image Image Image S. Mannestons 14. Goordinally Image Image <</td> <td>3. Motor Retardation 12. Senatic Concerns Teach to BPRS ID Number Profer Image: Senatic Concerns Teach to BPRS ID Number 4. Tencon 13. Guil Feelinge Image: Senatic Concerns Initid Image: Senatic Concerns Teach to BPRS ID Number 1. Mannesisses Protecting 14. Grondinally Image: Senatic Concerns Initid Image: Senatic Concerns Image: Senatic Concerns 6. Blanted Affect 15. Suppicourners Image: Senatic Content Incoments Image: Senatic Content Image: Senatic Content Indexate Image: Senatic Content Image: Senatic Content It Conceptual Discognization 17. Halkonatory Behavior</td> <td>Inone Weeks Internet Staff Spottage Staff Signature Internet Int</td> <td>Staff Tale MO During GAF (60) Earned Same Same Same Same Same Same Same Same</td> <td></td> <td>Internet in Patient Internet In Patient Internet Internet Rout Search 1</td> <td>80 802 9 X V</td> <td>Dista 10 Ward</td>	Ind Image 2. Excetored Withdravel 11. Hostilly Prove mild 3. Motor Retactation 12. Senatic Concerns Torre Image 4. Tension 12. Senatic Concerns Fore Image 4. Tension 12. Guilt Feelings Inid Image Image Image S. Mannestons 14. Goordinally Image Image Image Image S. Mannestons 14. Goordinally Image Image <	3. Motor Retardation 12. Senatic Concerns Teach to BPRS ID Number Profer Image: Senatic Concerns Teach to BPRS ID Number 4. Tencon 13. Guil Feelinge Image: Senatic Concerns Initid Image: Senatic Concerns Teach to BPRS ID Number 1. Mannesisses Protecting 14. Grondinally Image: Senatic Concerns Initid Image: Senatic Concerns Image: Senatic Concerns 6. Blanted Affect 15. Suppicourners Image: Senatic Content Incoments Image: Senatic Content Image: Senatic Content Indexate Image: Senatic Content Image: Senatic Content It Conceptual Discognization 17. Halkonatory Behavior	Inone Weeks Internet Staff Spottage Staff Signature Internet Int	Staff Tale MO During GAF (60) Earned Same Same Same Same Same Same Same Same		Internet in Patient Internet In Patient Internet Internet Rout Search 1	80 802 9 X V	Dista 10 Ward

The 4 forensic subgroups correspond to clinical presentations in the correctional environment: Forensic Type I, positive symptoms and hostility/aggressiveness; Forensic Type II, negative symptoms and neurocognitive dysfunction; Forensic Type III, affective instability associated with Forensic I or II; and Forensic Type IV, predominant Axis II pathology in conjunction with Forensic I, II, or III. These subgroups are described in more detail below. On the basis of subgroup assignment, the initial neuroleptic may also be augmented in a symptom-specific manner at this time. Subgroup scores are computed for the next 6-week period, and when the patient remains above the 40% threshold of symptom reduction established at 6 weeks (time of entry into subgroup), the second critical decision point is reached.

Critical decision point 2 of the algorithm stipulates the use of an atypical neuroleptic, regardless of the initial antipsychotic used. If the initial neuroleptic was an atypical, a different atypical neuroleptic must be utilized at week 12.

The third critical decision point occurs at week 18; if both of the first 2 neuroleptics were atypicals, the algorithm may be bypassed to the clozapine entry point, typically at 24 weeks. If not, the atypical neuroleptic may be augmented on the basis of symptom-specific parameters of the forensic subgroup.

Critical decision point 4 occurs at 24 weeks and is the entry point for all treatment-refractory patients. The PANSS is readministered to confirm the validity of the forensic subgroup, and a clozapine workup is performed if the patient fails to respond to all previous treatment efforts. Provided the patient is a good candidate, clozapine is begun and is titrated in the conventional manner.¹⁹

Critical decision point 5 occurs at 36 weeks; clozapine may be augmented with symptom-targeted psychotropic agents because of partial or inadequate response; clozapine levels should be rechecked and a workup for drug interactions performed.^{20,21}


Critical decision point 6 of the algorithm occurs at 52 weeks and signifies clozapine failure. The patient is gradually tapered off clozapine treatment, and a variety of medical, neuroleptic, and neuropsychological tests are administered.²²⁻²⁷

NONCOMPLIANCE ALGORITHM

Noncompliance with psychotropic medication, particularly by a patient who lacks capacity to make reasoned decisions, may be encountered at any point in the continuum of treatment. As shown in Figure 4, a serum test will confirm noncompliance for purposes of medical-legal documentation.

At this point, the automated prescribing summary (see Figure 2) can be discussed in a rational and nonthreatening manner with the patient, preferably with a member of the patient's family present (M. Finnerty, M.D., M. McLaughlin, Ph.D., unpublished guidelines, 1999). The

Figure 4. Management of Noncompliance




forensic division of the National Alliance for the Mentally Ill (NAMI) may also be contacted for their support of the family's efforts in behalf of treatment.

The options of oral atypical neuroleptics versus conventional intramuscular decanoate medications can be objectively presented to the patient. Decanoate formulations are often favored by inmates in correctional facilities because of the ease of administration.

If the patient refuses all neuroleptic agents, despite concerted efforts by the treatment team, family, and NAMI representatives, then the process of treatment-overobjection in the court system may be initiated. If the court hearing is successful and the patient receives intramuscular conventional neuroleptics (or chooses decanoate medications over oral agents), the treatment team focus should be to convert the patient to oral atypical neuroleptics and re-enter the treatment algorithm.

SIDE EFFECT ALGORITHM

The algorithm for conventional neuroleptic side effects (Figure 5) is introduced in the initial phases of treatment. A serum test will confirm compliance, for medical-legal documentation, and will also lend credence and validity to the patient's complaints regarding neuroleptic-induced side effects. If serum test results are negative for neuroleptics, then the noncompliance algorithm is indicated. Conventional neuroleptic side effects generally consist of extrapyramidal phenomena, including pseudoparkinsonian tremors, muscular dystonias, akinesia, and akathisia.²¹ These side effects may be controlled with a combi-



nation of benztropine, benzodiazepines, and propranoloh. If side effects persist, a switch to an atypical neuroleptic is indicated. Tardive dyskinesia should be diagnosed in its earliest stages, and the conventional neuroleptic discontinued. Some studies suggest that a course of treatment with vitamin E (800–1600 IU per day) benefits approximately one third of all such patients.²⁸ Resumption of treatment should commence with clozapine.²⁹ Another ominous toxic effect of neuroleptics is neuroleptic malignant syndrome (NMS).³⁰ Mortality secondary to clozapine-induced NMS is very rare.³¹

FORENSIC SUBGROUPS

At the 6-week mark of the algorithm, treatmentrefractory patients are administered another BPRS, the GAF, the Minnesota Multiphasic Personality Inventory-2 (MMPI-2), and the PANSS.²⁵ The BPRS is employed as an instrument to track clinical progress in the first 6 weeks of treatment. The PANSS is utilized to corroborate forensic subgroup assignment after 6 weeks and to validate these assignments should treatment failure occur. On the basis of the scores on these instruments, patients are assigned to 1 of 4 forensic subgroups. Patients with scores that overlap 2 subgroups, or whose scores are not congruous with their clinical presentation, may require specialized testing for confirmation of subgroup validity.³² For example, the Personality Assessment Screener (PAS)³³

Time	Clinical Intervention
On admission	Provide structured setting, psychoeducation, family and/or NAMI support
At 6 weeks	Transfer to continuing care; begin programming, eg, alternatives to violence, anger management evaluate for comorbid disorders such as substance abuse, PTSD, head trauma
At 12 weeks	Provide psychoeducation regarding change in medications, supportive psychotherapy; continue structured environment
At 18 weeks	Provide psychoeducation regarding change in medication, psychiatric rehabilitation
At 24 weeks	Transfer to clozapine ward for psychoeducation and programming package
At 36 weeks	Provide psychoeducation regarding future treatment; evaluate for transfer to outpatient mental health unit
At 52 weeks	Review APS with family, provide psychoeducation regarding future treatment alternatives, evaluate for ECT and other unconventional treatment modalities

has been divided into 10 clinical domains, including negative affect, social withdrawal, hostile control, acting out, anger control, and psychotic features. Neuropsychological testing with the Halstead-Reitan test²⁷ or Luria³⁴ involves a comprehensive battery of subtests that together reflect various areas of the brain and cognitive functioning. The MMPI-2²⁵ has a hypomania scale and the Millon Clinical Multiaxial Inventory-III (MCMI-III)³² has a bipolar scale; both are useful in assessing affective instability. There are also specialized tests for assessing the degree of hostility and aggressiveness, such as the Overt Aggression Scale.⁸⁵

Forensic Type I

Forensic Type I represents a hybrid of clinically relevant subscale items, drawn from the positive symptom and the hostility/aggressiveness subgroups. The 4 BPRS subscale items of Forensic I include uncooperative behavior, hostility, unusual thought content, and hallucinatory behavior. A Forensic I subgroup patient would typically present with command hallucinations, paranoid delusions, agitation, and aggressive behavior. The same design and methodology as employed in the first 6 weeks of BPRS testing applies to all of the forensic subgroup types. Therefore, if at 6 weeks a patient has a Forensic I subscale score of 28, the threshold would be set at 40%, or 17. The threshold is the degree of symptom severity reduction that must be obtained in 6 weeks of treatment. This decrement in overall symptom severity would constitute validation for continuation of the atypical neuroleptic currently utilized. Scores above the threshold would warrant augmentation or a change of neuroleptic.

Table 4. Forensic Type I: Treatment of Positive Symptoms With Hostility/Aggression, Weeks 6 to 24

Time	Pharmacologic Intervention
Week 1	Select any antipsychotic
Week 6	Utilize combination of conventional and atypical
	neuroleptics; augmentation with β -blocker,
	benzodiazepine, and/or mood stabilizer
Week 12	Select atypical antipsychotic
Week 18	Augment atypical neuroleptic with 2nd-choice
	neuroleptic, for example quetiapine and haloperidol
	Augment above with valproic acid, carbamazepine,
	lithium, or topiramate; β -blocker or clonidine; or
	Clonazepam
	Involve patient in structured programming
	Utilize seclusion or wrist-to-belt restraints if necessary,
	particularly for self-injurious behavior
	Avoid 4- and 5-point restraints due to high prevalence
	of abuse in history (eg, posttraumatic stress disorder)
Week 24	Begin clozapine (refer to clozapine treatment protocol,
	Tables 16–20)

Table 3 illustrates the inpatient environmental and programming sequence, beginning with Forensic I subgroup assignment (positive symptoms with aggression) at week 6 and extending through a hypothetical continuum of 52 weeks. Table 4 illustrates the Forensic I algorithm, with the subgroup assignment at week 6 and subsequent augmentation of the neuroleptic in a symptom-specific manner. This augmentation may be implemented prior to 6 weeks if necessary. A conventional neuroleptic may be combined with an atypical (e.g., haloperidol with lowdose risperidone) or augmented by the addition of a β-blocker, a benzodiazepine (low doses for short time intervals have proved useful due to y-aminobutyric acid [GABA]ergic effects), or an anticonvulsant such as divalproex sodium, carbamazepine, or topiramate.^{36,37} At 12 weeks, assignment to an atypical neuroleptic is mandatory for nonresponders. At 18 weeks, treatment-refractory patients may again receive symptom-specific augmentation, for example, quetiapine may be combined with haloperidol, olanzapine with loxapine, or risperidone with thioridazine.³⁸⁻⁴⁰ Unconventional agents for aggression such as clonazepam, clonidine, or naltrexone may be utilized.41-44 If the patient becomes uncontrollably agitated and aggressive, seclusion followed by wrist-to-belt restraints (i.e., preventive aggression devices) should be utilized in lieu of 4- or 5-point restraints.⁴⁵ Trauma assessments on all of these patients should be obtained on admission, since postrestraint counseling has been demonstrated to reduce recidivistic aggression.^{46,47} The clinical programming algorithm for the Forensic I subgroup in the prison environment (Table 5) includes a structured/low-stimulus setting (particularly for paranoid and aggressive individuals), psychoeducation, and family and/or NAMI support. Assessments for comorbid/dual disorders should include substance abuse (mentally ill chemical abusers), posttraumatic stress disorder (PTSD), developmental disabilities, and closed-head injuries (e.g., frontal lobe syndrome).48,49

Low-stimulus environment	
House initially in RCTP for stabilization	
Eventual transition to ICP or general population	
Program tracks:	
Anger management	
Psychotherapy	
MICA/dual recovery	
Continued psychopharmacology	

Forensic Type II

Forensic Type II includes BPRS and PANSS items representing negative and neurocognitive symptoms, i.e., motor retardation, blunted affect, poor attention span, and difficulty with abstractive thinking. Clinically, the Forensic II subgroup patients present with apathy, poor grooming and hygiene, cognitive processing deficits, and latency of response to questions posed by the interviewer. These patients typically occupy intermediate care program beds in correctional facilities for years; they remain undetected and elude admission by withdrawal from other inmates and staff. The negative symptoms of schizophrenia are both primary (associated with illness) and secondary (due to depression, neuroleptic induction of parkinsonism such as akinesia, or long-term use of conventional neuroleptic agents).⁵⁰ Negative symptoms, unlike positive symptoms, tend to endure and persist between exacerbations of acute illness.50 Negative symptoms have a functional location, that is, frontoparietal, suggesting a fundamental pathophysiologic distinction from positive symptoms.^{50,51} The cognitive dysfunction that accompanies some forms of schizophrenia also appears to be a distinct entity, predating the onset of psychotic symptoms by several years.⁵⁰ Schizophrenics with negative symptoms and those with cognitive dysfunction made similar errors on the Cognitive Psychology On-line Laboratory (COGLAB) Card Sort Test, a computerized version of the Wisconsin Card Sort Test, errors that were perseverative in nature, indicating some form of frontal lobe dysfunction.⁵² Negative symptomatology, frontal and soft neurologic signs, poor psychosocial performance, and cognitive impairment appear to be related phenomena in subgroups of schizophrenia.⁵¹

This algorithm begins with assignment to the Forensic II subgroup at week 6 and augmentation of the initial antipsychotic with a selective serotonin reuptake inhibitor (SSRI) (Table 6). Another less conventional strategy at week 6 would be the use of GABAergic compounds, such as benzodiazepines and valproate in combination with conventional neuroleptic agents; GABAergic compounds are associated with reduction in dopaminergic activity in the frontal lobes and may be useful in combating the "hypo-frontality" seen in this subgroup of schizophrenia.³⁶

Table 6. Forensic Type II: Pharmacologic Intervention for	
Negative Symptoms and Neurocognitive Dysfunction ^a	

Time	Pharmacologic Intervention
Week 1	First-line antipsychotic
Week 6	Symptom-specific augmentation: conventional
	neuroleptics plus an SSRI or divalproex; atypical
	neuroleptics plus an SSRI
Week 12	Switch to atypical if currently using conventional
	neuroleptic; if already using an atypical, switch to
	2nd-choice atypical
Week 18	Augmentation with 2nd-choice SSRI
	Augmentation with bupropion (avoid
	(dextroamphetamines and methylphenidate)
	Consider clozapine or ECT
	Involve patient in structured programming
	Neurocognitive training
	Avoid 4- and 5-point restraints, utilize wrist-to-belt
	restraint for self-injurious behavior
	Psychiatric rehabilitation
Week 24	Clozapine (refer to clozapine treatment protocol,
	Tables 16–20)
^a Abbreviati	ons: ECT = electroconvulsive therapy, SSRI = selective euptake inhibitor.

Week 12 of the algorithm signals a change of neuroleptic to an atypical antipsychotic; the best choices for this subgroup would be olanzapine or risperidone.⁵³ Week 18 allows for augmentation of the atypical with a secondchoice SSRI (other than that used at week 6), SSRI recommendations are fluoxetine and sertraline because of their intrinsic stimulatory properties. A second augmenting strategy at week 18 would be bupropion, which is a norepinephrine reuptake inhibitor and has a stimulatory property. Donepezil has also proved to be beneficial in cognitive dysfunction.⁵⁴ The clinical programming algorithm on an inpatient unit for Forensic II (Table 7) includes depression group at week 6 as well as evaluations for comorbid disorders such as substance abuse, developmental disabilities, learning disorders, closed-head injury (secondary to trauma), and PTSD (secondary to childhood and/or prison trauma).^{55,56} A useful technique utilized by trauma counselors, applicable to an intellectually and cognitively impaired population, is eye movement desensitization reprocessing.⁵⁷ The clinical programming tracks for Forensic II in prison are delineated in Table 8.

Forensic Type III

Forensic Type III represents the domain of 2 subgroups, 1 for affective instability associated with Forensic I symptoms (i.e., hypomanic) and the second for affective instability associated with Forensic II symptoms (i.e., depressive). The 4 BPRS/PANSS items in the Forensic II/ affective instability subscale (anxiety, depressed mood, poor attention, diminished abstractive capacity) and the 4 BPRS items in the Forensic I/affective instability subscale (hostility, grandiosity, unusual thought content, excitement) form Forensic III. Clinically, Forensic III patients present in 1 of 2 scenarios, i.e., 1 with grandiose delusions, psychomotor agitation, mood swings, and hostility;

 Table 7. Forensic Type II: Clinical Intervention for Negative

 Symptoms With Neurocognitive Dysfunction^a

Time	Clinical Intervention
On admission	Provide psychoeducation, supportive psychotherapy, family and/or NAMI support
At 6 weeks	Transfer to continuing care; begin programming (eg, depression group), evaluate for comorbid disorders, eg, substance abuse, PTSD, head trauma
At 12 weeks	Provide psychoeducation, insight-oriented psychotherapies, cognitive-behavioral training
At 18 weeks	Provide psychoeducation, continue psychotherapies and patient education
At 24 weeks	Transfer to clozapine ward for psychoeducation and programming package
At 36 weeks	Provide neurocognitive retraining; evaluate for transfer to outpatient mental health unit
At 52 weeks	Review APS with family; provide psychoeducation regarding future treatment alternatives; evaluate for ECT and other unconventional treatment modalities
^a Abbreviations a	re explained in the first footnote to Table 3.

Table 8. Clinical Programming for Forensic Type II: Negative Symptoms With Neurocognitive Dysfunction^a

High-stimulus environment

Then stillards environment
ICP transition with goal to re-enter general population
Special needs unit if applicable
Program tracks
MICA/dual recovery
Depression group
Psychiatric rehabilitation
Cognitive retraining
Psychotherapy
Continued psychopharmacology
^a Abbreviations are explained in the first footnote of Table 5.
24 , O.C.

the second with depression, anxiety, neurocognitive dysfunction, and suicidal ideation. The above 2 subgroups represent the entities known as schizoaffective disorder, bipolar and depressed types.⁵⁸

The pharmacologic algorithm for Forensic III is illustrated in Table 9. If the patient has a hypomanic presentation with marked mood swings, then augmentation would consist of valproic acid, topiramate, lithium, or carbamazepine.^{38,59–61} Clonazepam is useful for hypomanic states as an adjunctive agent until stability is achieved.³⁸ If the patient has a depressed appearance with anxiety or panic, social withdrawal, and self-injurious behaviors, but not suicidal ideation, augmentation consists of an SSRI (sertraline or paroxetine are recommended owing to effects on panic disorder and social anxiety, respectively).^{62,63} If suicidal ideation is present, electroconvulsive therapy (ECT) may be considered as an alternative to pharmacologic intervention.⁶⁴ Atypical antipsychotics of first choice for Forensic III are risperidone and olanzapine; risperidone is the preferred agent for the aggressive/hypomanic subgroups, and olanzapine is the preferred agent for the depressed or withdrawn clinical presentation.65,66 If the initial antipsychotic was risperidone on admission and the

Table 9. Forensic Type III: Pharmacologic Intervention for Affective Instability Weeks 6 to 24^a

Time	Pharmacologic Intervention
Week 1	First-line antipsychotic
Week 6	Symptom-specific augmentation
	If hypomanic or with marked mood swings, add valproic acid, carbamazepine, lithium, topiramate, or clonazepam
	If depressed without suicidal ideation, add SSRI to neuroleptic
	If depressed with suicidal ideation, evaluate for ECT with neuroleptic
Week 12	Switch to atypical if currently using conventional antipsychotic, switch to 2nd-choice atypical if using atypical
Week 18	Symptom-specific augmentation strategies If depressed, then olanzapine plus SSRI (2nd choice) or risperidone plus SSRI (2nd choice) If hypomanic with mood swings, then olanzapine plus lithium, valproic acid, or gabapentin or risperidone plus lithium, valproic acid, or gabapentin
Week 24	Clozapine (refer to clozapine treatment protocol, Tables 16–20)
^a Abbreviat	ions are explained in the first footnote to Table 6.

patient remains agitated, the second-choice atypical drug at week 12 should be quetiapine or olanzapine because of their beneficial effects on agitation and aggression.⁶⁷ The atypical antipsychotics are both dopamine and serotonin antagonists, in varying proportions, and have therapeutic clinical effects on psychosis, aggression, negative symp tomatology, neurocognitive dysfunction, and affective instability.⁶⁸ None of the atypical neuroleptics, with the exception of clozapine, has full schizophrenia-spectrum disorder symptom alleviation, which accounts for neuroleptic combinations and psychotropic-neuroleptic combinations recommended prior to week 24.69 Critical decision point 3 (week 18) requires augmentation of the atypicals with a second-choice SSRI (other than the one utilized at week 6) for depressed presentation and augmentation with mood-stabilizing agents for the hypomanic presentation. Gabapentin seems to possess moodstabilizing properties in affective instability; divalproex and topiramate are other choices.^{70–72} Table 10 delineates the clinical programming algorithm for Forensic III. Assessment for trauma, organicity, and substance abuse should have been accomplished by week 6. PTSD will exacerbate any underlying symptomatology in the schizophrenic spectrum; sertraline has recently been approved by the U.S. Food and Drug Administration for treatment of PTSD.73,74 The presence of organicity on Mini-Mental State Examination or on more elaborate neuropsychological testing should be addressed through the use of atypical neuroleptics, mood-stabilizing agents, SSRIs (also beneficial for autism and pervasive developmental disorder), and the avoidance of benzodiazepines and addicting psychostimulants such as methylphenidate.⁷⁵⁻⁷⁹ Table 11 addresses outpatient clinical programming and pharmacologic intervention.

Table 10. Forensic Type III: Clinical Intervention for Affective Instability^a

Time	Clinical Intervention
On admission	Provide structured setting, minimize stimulation, family and/or NAMI support
At 6 weeks	Transfer to continuing care; begin programming (eg depression group therapy); evaluate for comorbid disorders, eg, substance abuse, PTSD, head trauma
At 12 weeks	Provide psychoeducation, insight-oriented psychotherapies, group therapy
At 18 weeks	Provide psychoeducation; continue psychotherapies, psychiatric rehabilitation, OT/RT
At 24 weeks	Transfer to clozapine ward for psychoeducation and programming package
At 36 weeks	Provide bipolar and depression group therapy; evaluate for transfer to outpatient mental health unit
At 52 weeks	Review APS with family; provide psychoeducation regarding future treatment alternatives; evaluate for ECT and other unconventional treatment modalities
	OT = occupational therapy, RT = recreational therapy; ons are explained in the first footnote to Table 3.

Table 11. Clinical Programming for Forensic Type III: Affective Instability^a

Low-stimulus environment

House initially in RCTP for stabilization

Eventual transition to ICP or general population

Program tracks

Anger management

Depression/bipolar group therapy

MICA/dual recovery Continued psychopharmacology

^aAbbreviations are explained in the first footnote to Table 5.

Forensic Type IV

Forensic Type IV is the most complex of all subgroups with respect to overall management owing to the predominant underlying Axis II disorder. There must be accurate subgroup placement in Forensic I, II, or III, along with recognition of elevated scores on the MMPI-2, PAS, and/or MCMI-III.^{25,32,33} Table 12 illustrates the treatment algorithm through week 24. Pharmacotherapy of the Forensic IV subgroup is based upon the same treatment rendered to the other 3 subgroups; in addition, atypical neuroleptics have proven efficacy in Cluster B types, such as borderline personality disorders. Assignment of borderline personality patients to a dialectic behavioral therapy ward after alleviation of Axis I symptoms is the recommended therapeutic progression.^{80,81} Seclusion and shortterm wrist-to-belt restraints (variation of preventive aggression devices) are preferable to 4- or 5-point restraints in the event of aggression or self-injurious behaviors.⁴⁵ Table 13 delineates the inpatient clinical programming tracks for Forensic IV and is consistent with the preceding description of specialized therapies. Table 14 illustrates programming tracks for Forensic IV in prison for inmate-

	Forensic Type IV: Pharmacologic Intervention for ht Axis II Disorder, Weeks 6 to 24 ^a
Time	Pharmacologic Intervention

THIE	i narmaeologie intervention
Week 6	Assign to Forensic I, II, or III based on prevalent
	symptoms and treat according to subgroup-specific
	pharmacologic algorithm
	Administer PANSS and other personality
	inventories
	Assign to behavioral unit with dialectic behavior
	therapy
	Wrist-to-belt restraints on short-term basis for
	self-abuse and/or aggression
	Structured programming
Week 24	Clozapine (refer to clozapine treatment protocol,
	Tables 16–20)
^a Abbreviat	ion: PANSS = Positive and Negative Syndrome Scale.

patients who are not subject to disciplinary placement in SHUs (see Table 2) upon their return.

The more complex situation is encountered with the inmate-patient returning to an SHU (Figure 6). A proposal for treatment of this patient comprises admission to an RCTP on return from the inpatient hospital (see Figure 6; Table 15). The patient would be transferred from the RCTP to a hypothetical ICP-SHU (see Table 2) upon clinical improvement; if no clinical improvement occurs, the patient would be returned to the hospital. The ICP-SHU proposal advances the design of an intermediate environment with 4 to 6 hours of programming per day, i.e., a disciplinary structure with increased psychiatric programming.

CLOZAPINE ALGORITHM

Clozapine is the choice neuroleptic after 18 to 24 weeks of treatment with conventional and atypical antipsychotics, in some instances augmented by other psychotropic medications.^{82,83} Clozapine has been positioned in the algorithm to be the medication utilized after failure of both a conventional neuroleptic and an atypical neuroleptic, or 2 atypical neuroleptic failures. There is limited justification for the use of clozapine as an initial neuroleptic in the early stages of the algorithm owing to its potential for life-threatening side effects. Clozapine has confirmed efficacy in refractory symptomatology, such as aggression, neurocognitive dysfunction, affective instability with associated self-injurious behaviors, and suicide, and even in borderline personality disorders with aggressive behaviors.^{84–86} It is also effective in the phenomenon of compulsive water-drinking.87 Clozapine has relatively high dopamine-1 (D_1) , low D_2 , and high serotonin-1 and -2 (5-HT₁ and 5-HT₂) receptor affinity, accounting for the lack of extrapyramidal effects and the antiaggressive effect.^{29,88,89} The primary metabolism of clozapine is controlled by cytochrome P450 1A2 (CYP1A2), which is influenced by a number of psychotropic agents, notably the SSRIs fluoxetine and fluvoxamine; fluvoxamine can increase the serum level of clozapine 10-fold in a period of

Table 13. Forensic Type IV: Clinical Intervention for Personality Disorder^a

Time	Clinical Intervention
On admission	Provide highly structured, consistent setting, psychoeducation, family and/or NAMI support
At 6 weeks	Transfer to dialectic behavior therapy ward; provide programming on ward; evaluate for comorbid disorders, eg, substance abuse, PTSD head trauma
At 12 weeks	Provide psychoeducation, dual therapy for MICA; encourage participation in Alcoholics Anonymous and Narcotics Anonymous; utilize restraints and/or seclusion if necessary to prevent self-injurious behaviors
At 18 weeks	Provide psychoeducation, continue psychotherapies, dual therapy for MICA, dialectic behavior therapy
At 24 weeks	Transfer to clozapine ward for psychoeducation and programming package
At 36 weeks	Administer drug screens and check serum levels; continue substance abuse groups and behavioral program; evaluate for transfer to outpatient mental health unit
At 52 weeks	Review APS with family; provide psychoeducation regarding future treatment alternatives; evaluate for ECT and other unconventional treatment modalities; evaluate for transfer to borderline treatment units at correctional facilities

Table 14. Clinical Programming for Forensic Type IV: Personality Disorders, Not in Special Housing Unit^a

Neutral stimulus environment

Return to originating correctional facility or mental health service Program tracks

Anger management

MICA/dual recovery


For antisocial personality disorder, behavior modification program For borderline personality disorder, dialectic behavior therapy Continued psychopharmacology

^aAbbreviation: MICA = mentally ill chemical abusers.

7 to 14 days.⁹⁰ The events at 24 weeks include tapering the patient off all other psychotropic agents and performing a clozapine workup, which is both medical and psychiatric in nature. Psychiatric workup includes the PANSS for confirmation of subgroup assignment, an assessment of compliance due to the necessity for weekly serum levels (clozapine levels and complete blood count with differential), and psychoeducation in the form of an orientation to the benefits of clozapine (Table 16).

Side effects secondary to clozapine administration are divided into minor versus serious (toxic effects) and fall along a continuum of common to rare events. The clozapine side effects algorithm includes tachycardia, orthostatic hypotension with associated dizziness, weight gain, constipation, and minor extrapyramidal symptoms.²⁹ The respective remedies for these side effects are delineated in Figure 7. Seizures can usually be controlled with phenytoin, but poor control with 1 or more anticonvulsants may

Figure 6. Clinical Programming for Forensic Type IV: Personality Disorders in Proposed Intermediate Care Program-Special Housing Unit (ICP-SHU) Setting^a



Evaluate for transfer to ICP-SHU

Programming and treatment successful

Evaluate to reduce SHU time Transfer to least restrictive treatment setting

Psychiatric follow-up


^aAbbreviations: CNYPC = Central New York Psychiatric Center (prison hospital), OMH-DOCS = Office of Mental Health-Department of Corrections; other abbreviations are explained in the first footnote to Table 5.


dictate clozapine discontinuation (phenytoin may also decrease serum clozapine levels by 50%).⁹¹ Figure 8 also illustrates the serious, life-threatening toxic side effect known as agranulocytosis.92 This should always be suspected with sore throat, fever, candidiasis, a white blood cell count below 3000/mm³, and a granulocyte count in the 1000 to 1500/mm³ range.⁹² The clinician has 2 options in the event of agranulocytosis: (1) continue clozapine at a reduced dosage, monitor the complete blood and granulocyte count closely in protective isolation, and utilize

Table 16. Clozapine Stage: 24 Weeks ^a
Clozapine medical workup
Administer PANSS and reassign if necessary to correct forensic
subgroup assignment
Taper all other psychotropic medications and begin titration with clozapine on recommended schedule
1
Weekly complete blood count and subscale testing

^aAbbreviation: PANSS = Positive and Negative Syndrome Scale.








granulocyte colony-stimulating factor; (2) discontinue the clozapine, begin another atypical neuroleptic, and track the subscale scores and clinical condition of the patient.⁹²

Figure 8 illustrates the toxic side effect of hyperglycemia, encountered in treatment with clozapine and its related neuroleptic, olanzapine. Both clozapine and olanzapine induce hyperglycemia, which may be because of weight gain.^{93–95} Clozapine dosage, as has been suggested in recent literature, can be decreased and an augmentation dosage of quetiapine begun (i.e., 50-200 mg/day) with the same therapeutic efficacy and a decreased side effect profile.⁹⁶ Another strategy is the use of the SSRI fluvoxamine, which competes with clozapine/norclozapine metabolism at the CYP1A2 site, increasing serum levels of clozapine exponentially.90 A relatively small daily dosage of clozapine can, therefore, be used, and a reduced side effect profile obtained. Other side effects associated with clozapine treatment include sialorrhea, NMS (discontinue clozapine), cardiac arrhythmias (treat medically), and anticholinergic toxicity (treat supportively).²⁹

Clozapine must be initiated in a treatment setting where medical supervision is available. There is a specific practice guideline¹⁹ for the initiation of clozapine by which the



oral dosage of 350 to 400 mg/day may be achieved by the second week of treatment. The usual therapeutic dosage is 300 to 700 mg/day with a maximum of 900 mg/day (in divided doses).

Serum clozapine levels should be obtained 12 hours after last administration, and the recommended therapeutic window is 250 to 350 ng/mL. The "threshold" is 350 to 420 ng/mL, above which linear (dose-related) side effects and toxicity increase dramatically.^{19,97}

The partial or inadequate response to clozapine is addressed in Table 17; partial therapeutic response due to drug interactions is addressed in Tables 18 and 19. At week 36, clozapine may be augmented with a conventional neuroleptic (e.g., haloperidol, 5-10 mg/day) or an atypical neuroleptic (e.g., risperidone, 1-3 mg/day) for Forensic I (positive symptoms and aggression) and Forensic II (negative symptoms and neurocognitive dysfunction), respectively.98,99 Forensic III (bipolar/hypomanic type) may have clozapine augmented with anticonvulsants or lithium (although lithium and clozapine may predispose the patient to NMS)^{87,100-103}; Forensic III (depressed type) may have augmentation with ECT if suicidal and with SSRIs if not suicidal (avoid fluoxetine and fluvoxamine).^{64,90,104} Combinations of clozapine and carbamazepine should be avoided because of immunosuppressive potential.¹⁰⁵ Since clozapine is highly anticholinergic, crisis due to combinations with drugs with such potential may lead to narrow-angle glaucoma and paralytic ileus.²⁹ Phenytoin induces the cytochrome P450 system and may decrease clozapine levels by 65% to 85%.¹⁰⁶ Clozapine and other epileptogenic agents, such as bupro-

Table 17. Partial Response to Clozapine: Drug Augmentation at Week 36^{a}

Forensic Type	Treatment		
Ι	Clozapine and conventional neuroleptic		
	(eg, haloperidol)		
II	Clozapine and atypical neuroleptic		
	(eg, risperidone)		
III	Hypomanic: Clozapine plus divalproex or lithium		
	Depressed: Clozapine plus ECT (if suicidal);		
	Clozapine plus SSRIs (if not suicidal)		
IV	Utilize Forensic Type I, II, or III as applicable to		
	clinical presentation		
^a Abbreviations an	re explained in the first footnote to Table 6.		

Table 18. Clozapine Augmentation: Drug-Drug Interactions, Weeks 36 to 52

Avoid combination of carbamazepine plus clozapine

Watch for anticholinergic crisis with combinations of atypicals, conventionals, psychostimulants

- Phenytoin plus clozapine may reduce steady-state clozapine levels by 65% to 85%
- Clozapine plus benzodiazepines, especially lorazepam, may cause sedation and sialorrhea
- Carefully monitor the following medications in combination with clozapine:
 - Fluvoxamine Pemoline Methylphenidate Carbamazepine Bupropion

Thioridazine Lorazenam

Phenytoin

Table 19. Inadequate Response to Clozapine at 52 Weeks

Check length of trial, should be at least 3 to 6 months Check plasma level (therapeutic range, 250–350 ng/mL) Evaluate compliance

Check drug-drug interactions (cytochrome P450 [CYP] system enzyme inhibition, enzyme CYP1A2 involved in clozapinefluvoxamine inhibition)

Confirm principal diagnosis

Perform neuropsychiatric evaluation

pion and maprotiline, should be avoided. Clozapine and benzodiazepines (particularly lorazepam) may cause excessive sedation and sialorrhea.²⁹ Clozapine and certain SSRIs may result in dramatically increased serum clozapine levels.⁹⁰

Clozapine Failure at 52 Weeks

Table 20 illustrates clozapine failure after 52 weeks of treatment. At this point the following should be accomplished:

- Clozapine should be gradually decreased over a 1- to 2-week period of time.
- A complete battery of psychological testing may be considered, including the PANSS, the Psycho-

pathology Checklist-Revised (Violence Risk Appraisal Guide assessment), the Mini-Mental State Examination, and the MMPI-2 and MCMI-III for purposes of reevaluating core psychopathology as well as comorbid conditions and Axis II psychopathology.^{15,25,32,107}

- Medical workup should include basic laboratory testing of blood and urine, a heavy metal screen, a chest x-ray, and an electrocardiogram (ECG).
- Neurologic workup should include examination, electroencephalogram, computed tomography scan, and magnetic resonance imaging of the brain.
- Neuropsychological testing may include the Wisconsin Card Sort Test and other tests to rule out previously undetected organicity.
- Serum/urine screen and a substance abuse evaluation should be conducted to detect drugs of abuse.
- A trial of naltrexone (50–100 mg/day) may be helpful in distinguishing substance abuse.¹⁰⁸

With completion of the postclozapine workup, the following unconventional trials may be considered for this most refractory group of diagnosed schizophrenic patients:

- Combinations of 2 atypical neuroleptics, such as risperidone, quetiapine, and olanzapine
- Combinations of atypical neuroleptics with pimozide; monitor ECG weekly for arrhythmias and conduction abnormalities^{109,110}
- Two atypical neuroleptics, such as risperidone and olanzapine, and augmentation with lithium, an SSRI, divalproex, or ECT
- One or 2 atypical neuroleptics, in combination with a tricyclic antidepressant such as desipramine or a monoamine oxidase inhibitor such as phenelzine.

THE AUTOMATED PRESCRIBING SUMMARY AND RECOMMENDED DOSAGE RANGES FOR PSYCHOTROPIC MEDICATIONS

The Automated Prescribing Summary (see Figure 2) was developed to give the clinician an overview of the patient's 10-year treatment history (M. Finnerty, M.D., M. McLaughlin, Ph.D., unpublished guidelines, 1999). Included in the chart are the facility and prescribing physician names; active psychotropic medications with start and stop dates; duration of the medication in months; categorization of dosage as within, greater than, or less than the recommended range; indication whether minimum dose was sustained for more than 5 days; and indication whether maximum dose trial was sustained for more than 6 weeks.

Because it is important to maintain the patient at or near maximum recommended dosage for a sustained period of time, it may be necessary to rapidly titrate certain

Table 20. Clozapine Failure at 52 Weeks ^a
Taper off clozapine gradually
Administer PANSS, Mini-Mental State Examination, VRAG, personality inventories
Complete medical workup with laboratory testing (especially metabolic factors)
Neurologic examination and neurologic testing
Blood urine for drug screen
Substance abuse workup/trial of naltrexone
Consider ECT and lithium workups
Two atypical antipsychotics
Two atypicals and ECT, lithium, SSRI, or haloperidol
Atypical antipsychotic and pimozide and/or fluvoxamine
NIMH experimental antipsychotic outcome studies
^a Abbreviations: ECT = electroconvulsive therapy, NIMH = National Institute of Mental Health, PANSS = Positive and Negative Syndrome Scale, SSRI = selective serotonin reuptake inhibitor, VRAG = Violence Risk Appraisal Guide.

primary psychotropic medications while targeting specific symptom reduction. Recent research suggests that patients tolerate divalproex with rapid loading techniques, as well as with slow dosage titration.¹¹¹ While one may argue against this approach from the standpoint of receptor-site saturation (first-time psychotic episodes may only require 65% D₂ receptor saturation with haloperidol), it is an accepted fact in forensic facilities that psychiatrists are prescribing to manage Axis I symptomatology and control aggressive or self-injurious behaviors.¹¹²

Tables 21 and 22 detail the psychotropic medication(s) utilized in this algorithm with suggested dosage ranges for utilization both as an agent in monotherapy and as an adjunctive agent.

PROJECT IMPLEMENTATION AND OUTCOME MEASURES

Evidence-based practice guidelines provide recommendations based on a synthesis of the scientific literature concerning treatment for certain disorders, in this instance, schizophrenia.¹¹³ There are both clinical and administrative reasons to believe that implementing such algorithms in mental health systems will be useful in improving outcomes, containing costs, predicting costs with greater accuracy, and utilizing resources in a more efficacious manner.¹¹⁴⁻¹¹⁶

The implementation of such medication algorithms will involve key strategies and principles germane to all such projects¹¹⁴: (1) stakeholder involvement throughout development and implementation (for example, the Office of Mental Health and Department of Corrections); (2) provision of education and technical assistance to clinicians, patients, and families (such as BPRS, PANSS, and GAF training, psychoeducation, and NAMI involvement); and (3) administrative support and modification of system structure (i.e., creation of ICP-SHU intensive treatment units as an alternative to disciplinary housing for the seriously and persistently mentally ill population).

Table 21. Dosage Ranges of	Monotherapy ^a	Table 22. Dosage Ranges of A	Table 22. Dosage Ranges of Adjunctive Medications ^a	
Drug	Dosage Range (mg/d)	Drug	Dosage Range (mg/d)	
Antipsychotics		Antipsychotics		
Haloperidol	10-40	Haloperidol	5-10	
Haloperidol decanoate	150–400 mg q 4 wk	Haloperidol decanoate	75–150 mg q 4 wk	
Fluphenazine	10-40	Pimozide	0.5-2	
Fluphenazine decanoate	25–75 mg q 4 wk	Fluphenazine	5-10	
Pimozide	1-4	Fluphenazine decanoate	12.5–37.5 mg q 4 wk	
Loxapine	50-200	Thioridazine	100-400	
Perphenazine	16-64	Loxapine	25-100	
Thioridazine	300-800	Perphenazine	4–16	
Risperidone	2-8	Risperidone	1–3	
Olanzapine 🔿	10-20	Quetiapine	100-250	
Quetiapine	300-800	Olanzapine	5-10	
Clozapine	300-700 20-60 50-200 20-50 150-300 15-45 150-300	Antidepressants		
Antidepressants		Fluoxetine	10-30	
Fluoxetine	20-60	Sertraline	25–100	
Sertraline	50-200	Paroxetine	10-30	
Paroxetine	20–50	Fluvoxamine	50-100	
Fluvoxamine	150-300	Venlafaxine	75–150	
Mirtazapine	15-45	Mirtazapine	15-30	
Venlafaxine	150-300	Nefazodone	100-250	
Bupropion	150-400	Bupropion	100–250	
Nefazodone	250-500	Desipramine	50-150	
Desipramine	50-150	Trazodone	150-300	
Phenelzine	15-60		150-500	
Trazodone	300-600	Mood stabilizers	750 1500	
Mood stabilizers		Divalproex	750–1500	
Divalproex	1000-3000 (20-30 mg/kg/d)	Gabapentin	600-1800	
Gabapentin	900–3600	Lamotrigine	150-250	
Topiramate	50-200	Topiramate	25-100	
Lamotrigine	250–500	Lithium	900–1500	
Clonazepam	2–6	Clonazepam	1–3	
Lithium	1200–2400	Antiparkinsonians		
Antiparkinsonians	4	Benztropine	1–2	
Benztropine	1-4	Propranolol	20-40	
Propranolol	20–60	Sedative-hypnotics		
Sedative-hypnotics	$\begin{array}{c} 500 - 200 \\ 250 - 500 \\ 2 - 6 \\ 1200 - 2400 \\ \end{array}$ $\begin{array}{c} 1 - 4 \\ 20 - 60 \end{array}$	Hydroxyzine	50-100	
Hydroxyzine	100-200	Zolpidem	5	
Zolpidem	5-10	^a From the Expert Consensus Gui	delines ¹⁰ Multiple medications	
^a From the Expert Consensus Gu	idelines. ¹⁰	same class.		
r				

The implementation of this forensic algorithm project will be accomplished in the following manner.

Phase I

1. Prior to the introduction of medication algorithms, physicians in the inpatient and outpatient sector will conduct patient interviews and perform assessments with the BPRS and GAF. The population of patients will include all patients with a DSM-IV diagnosis of schizophrenia, schizoaffective disorder, and psychotic disorder NOS. In the outpatient setting, these patients will be assessed on admission to and discharge from the inpatient hospital and monthly for 6 months. Inpatients will be assessed at the time of admission, weekly for 6 weeks, at the time of treatment planning, and weekly for the 6 weeks prior to discharge. Automated prescribing summaries will be available to the physicians (see Figure 2). Assessment data will be initially in paper form and eventually Web

based for computerized analysis (see Figure 3). Physicians will not be influenced by the structure provided by practice guidelines and treatment algorithms. The data collected from this prealgorithm project phase will serve as control/baseline outcomes.

2. Outcome measurements for this phase of the project will be divided into clinical instruments and other parameters of patient functioning. The clinical instruments utilized, i.e., the BPRS and GAF, have demonstrated reliability and validity for schizophrenia. The other parameters measured will include restraints/seclusion (data collected through Security Information Management Systems), recidivism rates, length of stay, incidents, and patient quality of life.^{117–119} The Quality of Life Inventory¹²⁰ will be modified for the correctional environment so that a survey instrument will provide data, regarding adaptability to prison, as a direct result of psychiatric treatment. Outcome assessments should use representative samples and

appropriate scientific design, and outcomes should be reassessed at clinically meaningful points in time.¹²¹

Phase II

1. The FAP infrastructure will be applied to the same correctional population. A BPRS will be administered to the patient by the physician at the time of admission and once weekly for the first 6 weeks of hospitalization. If there is at least 40% reduction in symptom severity with the initial antipsychotic, then a PANSS need not be administered. The chief psychologist will administer the BPRS and PANSS at 6 weeks in the absence of 40% reduction, and based on resulting scores, subgroup assignment will occur.

Data from the BPRS, PANSS, subscale instruments, and GAF will be paper based initially and eventually Web based for computerized analysis. While the BPRS, PANSS, and GAF all have demonstrated validity and reliability, this will be an important determination with respect to items in the forensic subscale instruments. These forensic subscale items must accurately represent the clinical entities undergoing treatment, and interrater reliability must also be established. Lack of either reliability or validity may cause amendment of forensic subscale items.

2. The same outcome assessment tools and measurements will be used, following use of the forensic algorithm, as were employed in Phase I. Comparisons will be made between restraints/seclusion rates, incidents, lengths of stay, recidivism rates, and quality-of-life measurements for the population treated in Phase I and in Phase II of this project. Our research hypothesis is that the FAP, consisting of all of the aforementioned tools and methodology, will lead to significant reduction in patient symptoms and improvement in patient functioning in a comparison with prealgorithm treatment efforts.

SUMMARY

This forensic/correctional algorithm was designed as an instrument through which a total care package for the schizophrenic inmate could be delivered, via a number of prescriptive critical decision points along a continuum of treatment. Schizophrenia was viewed not only as a form of psychotic disorder but also as a heterogeneous entity with various clinical presentations. Changes in the primary neuroleptic, augmentation with other psychotropic medications, the introduction of clozapine as the common pathway for refractory individuals, and the programming choices matched to clinical symptomatology and subtype were all depicted along the path of this algorithm.¹²² The algorithm permits movement of the inmate-patient from the inpatient hospital to the outpatient correctional environment based on the 4 proposed forensic subtypes and the 4 corresponding treatment tracks. The purpose of this intricate FAP is the provision of state-of-the-art psychiatric services to the incarcerated seriously and persistently mentally ill population. Its validity and effectiveness have yet to be demonstrated.

Drug names: benztropine (Cogentin and others), bupropion (Wellbutrin), carbamazepine (Tegretol and others), clonazepam (Klonopin and others), clonidine (Catapres and others), clozapine (Clozaril and others), desipramine (Norpramin and others), diphenhydramine (Benadryl and others), divalproex sodium (Depakote), donepezil (Aricept), fluoxetine (Prozac), fluvoxamine (Luvox), gabapentin (Neurontin), haloperidol (Haldol and others), hydroxyzine (Atarax and others), lamotrigine (Lamictal), lorazepam (Ativan and others), loxapine (Loxitane and others), methylphenidate (Ritalin and others), mirtazapine (Remeron), naltrexone (ReVia), nefazodone (Serzone), olanzapine (Zyprexa), paroxetine (Paxil), pemoline (Cylert), perphenazine (Trilafon and others), phenelzine (Nardil), phenytoin (Dilantin and others), pimozide (Orap), propranolol (Inderal and others), quetiapine (Seroquel), risperidone (Risperdal), sertraline (Zoloft), thioridazine (Mellaril and others), topiramate (Topamax), trazodone (Desyrel and others), valproic acid (Depakene and others), venlafaxine (Effexor), zolpidem (Ambien).

REFERENCES

- 1. Beck A, Gilliard D, Greenfeld L, et al. Survey of state prison inmates, NCJ-136949 (1991). Rockville, Md: US Dept Justice, Office of Justice Programs, Bureau of Justice Statistics; 1993. NCJ-136949
- Daniels J, ed. Kendra's Law: the process for obtaining assisted outpatient treatment. OMH Quarterly 1999;5(3):4–7
- 3. Eng v Coughlin et al, 80~CV-00385 (WD NY 1998)
- Grassian S, Psychopathological effects of solitary confinement. Am J Psychiatry 1983;140:1450–1454
- Grassian S. Effects of sensory deprivation in psychiatric seclusion and solitary confinement. Int J Law Soc 1986;8:49–65
- Faulkner LR, Practice guidelines in forensic psychiatry. American Academy of Psychiatry and the Law [newsletter]. 1999;24(2):1
- Glancy GD, Regehr C. The forensic psychiatric aspects of schizophrenia. Psychiatr Clin North Am 1992;15:575–589
- American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997;154(suppl 4): 1–63
- Lehman AF, Steinwachs DM, and the Coinvestigators of the PORT Project. Translating research into practice the schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1–10
- Expert Consensus Guideline Series: Treatment-of Schizophrenia. J Clin Psychiatry 1996;57(suppl 12B):1–58
- Miller AL, Chiles JA, Chiles JK, et al. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999;60: 649–657
- Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799–812
- Global Assessment of Functioning (GAF) Scale. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:32
- 14. Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine and haloperidol in first-episode psychosis. Am J Psychiatry 1999;156:79–87
- Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276
- Kay SR, Opler LA. The positive-negative dimension in schizophrenia: its validity and significance. Psychiatr Dev 1987;5:79–103
- 17. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the Posi-

tive and Negative Syndrome Scale for schizophrenics. Psychiatry Res $1988;\!23\!:\!99{-}110$

- Gur RE, Mozley PD, Resnick SM, et al. Relations among clinical scales in schizophrenia. Am J Psychiatry 1991;148:472–478
- Conley RR. Optimizing treatment with clozapine. J Clin Psychiatry 1998; 9(suppl 3):44–48
- Pies R. Schizoaffective disorder: mixing moods and madness. Psychiatr Times 1996;13:1–4
- Meltzer HY, Lee MA, Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr Scand Suppl 1994;384:95–101
- Andreasen NC. Negative symptoms in schizophrenia. Arch Gen Psychiatry 1982;39:784–788
- Andreasen N. Modified scale for the assessment of negative symptoms. In: NIMH Treatment Strategies in Schizophrenia Study. (ADM) 9-102. Rockville, Md: US Dept Health Human Services, Public Health Administration; 1984
- Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Br J Psychiatry 1989;155(suppl 7):53–58
 Butcher JN, Dahlstrom WG, Graham JR, et al. Minnesota Multiphasic
- Butcher JN, Dahlstrom WG, Graham JR, et al. Minnesota Multiphasic Personality Inventory-2: manual for administration and scoring. Minneapolis, Minn: University of Minnesota Press; 1985
- Heaton RK, Chelune GJ, Talley JL, et al. Wisconsin Card Sorting Test manual (revised). Odessa, Fla: Psychological Assessment Resources; 1993
- Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson Ariz: Neuropsychology Press; 1985
- Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996;57:167–173
- Lieberman JA. Maximizing clozapine therapy: managing side effects. J Clin Psychiatry 1998;59(suppl 3):38–43
- Parks-Veal PM. Revisiting neuroleptic malignant syndrome. Consultant Pharmacist 1997;12(6):1–3
- Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997;8:671–677
- Millon T, Davis R, Millon C. Millon Clinical Multiaxial Inventory-III (MCMI-III). 2nd ed. Minneapolis, Minn: NCS; 1997
- Morey LC. Personality Assessment Screener (PAS) professional manual Lutz, Fla: Psychological Assessment Resources; 1997
- Luria AR. Higher Cortical Function in Man. New York, NY: Basic Books; 1966
- Yudofsky SC, Silver JM, Jackson W, et al. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 1986;143:35–39
- Wassef AA, Dott SG, Harris A, et al. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 1999;19: 222–232
- Williams DT, Mehl R, Yudofsky SC, et al. The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. J Am Acad Child Psychiatry 1982;21:129–135
- Citrome L, Volavka J. Management of violence in schizophrenia. Psychosom Ann 2000;30:41–52
- Buckley PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry 1999; 60(suppl 10):52–60
- Kapur S, Zipursky R, Remington G, et al. PET evidence that loxapine is an equipotent blocker of 5-HT₂ and D₂ receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 1997;154:1525–1529
- 41. Sandman CA. An orally administrated opiate blocker, naltrexone, attenuates self injurious behavior. Am J Ment Retard 1990;95:93–102
- 42. Volavka J. Can aggressive behavior in humans be modified by beta blockers? Postgrad Med 1988;Feb 29(spec no.):163–168
- Sorgi PJ, Ratey JJ, Polakoff S. Beta-adrenergic blockers for the control of aggressive behaviors in patients with chronic schizophrenia. Am J Psychiatry 1986;143:775–776
- Keats MM, Mukherjee S. Antiaggressive effect of adjunctive clonazepam in schizophrenia associated with seizure disorder. J Clin Psychiatry 1988;49:117–118
- Van Rybroek GJ, Kuhlman TL, Maier GJ, et al. Preventive aggression devices (PADS): ambulatory restraints as an alternative to seclusion. J Clin Psychiatry 1987;48:401–405
- Foa EB, Riggs DS, Dancu CV, et al. Reliability and validity of a brief instrument for assessing post-traumatic stress disorder. J Trauma Stress

1993;6:459-473

- Opdyke D. Eye movement desensitization and reprocessing treatment of rape trauma: a case report. Treating Abuse Today [newsletter] March-April 1997:9–12
- Hwang MY, Bermanzohn PC, eds. Management of Schizophrenia With Comorbid Conditions. Washington, DC: American Psychiatric Association. In press
- Neppe VM, Goodwin GT. The neuropsychiatric evaluation of the closed head injury of transient type (CHIT). In: Varney N, Roberts R, eds. Evaluation and Treatment of Mild Traumatic Brain Injury. Mahwah, NJ: Erlbaum and Associates; 1999:149–208
- Tamminga CA, Buchanan RW, Gold JM. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 1998;13(suppl 3):S21–S26
- Wong AH, Voruganti LN, Heselgrave RJ, et al. Neurocognitive deficits and neurological signs in schizophrenia. Schizophr Res 1997;23: 139–146
- Capleton RA. Cognitive function in schizophrenia: association with negative and positive symptoms. Psychol Rep 1996;78:123–128
- Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407–418
- Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000;157:4–15
- Ries R, Comtois K. Illness severity and treatment services for dually diagnosed severely mentally ill outpatients. Schizophr Bull 1997;23:239–246
- Buckley PF. Substance abuse in schizophrenia: a review. J Clin Psychiatry 1998;59(suppl 3):26–30
- Shapiro F. Eye movement desensitization and reprocessing (EMDR): evaluation of controlled PTSD research. J Behav Ther Exp Psychiatry 1996;27:209–218
- Evans JD, Heaton RK, Paulsen JS, et al. Schizoaffective disorder: a form of schizophrenia or affective disorder? [CME] J Clin Psychiatry 1999; 60:874–882
- 59. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry 1989;
 50(3, suppl):23–29
- Morinigo A, Martin J, Gonzalez S, et al. Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside J Clin Psychiatry 1989; 11:199–207
- Alam MY, Klass DB, Luchins DJ, et al. Effectiveness of divalproex sodium, valproic acid and carbamazepine in aggression. Presented at the 35th annual meeting of New Clinical Drug Evaluation Unit; May 31– June 3, 1995; Orlando, Fla
- Wolkow R, Apter J, Clayton A, et al. Double-blind flexible dose study of sertraline and placebo in patients with panic disorder. Presented at The 20th Congress of the College of International Neuropsychopharmacology; June 23–27, 1996; Melbourne, Australia
- Stein MB, Liebowitz MR, Lydiard BR, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998;280:708–713
- National Institutes of Health Consensus Development Conference. Electroconvulsive therapy. Natl Inst Health Consens Dev Conf Consens Statement 1985;5(11):11–16
- Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996;57 (suppl 11):68–71
- Rosen EH. Olanzapine and negative symptoms [letter with reply]. J Clin Psychiatry 1998;59:537
- Meats P. Quetiapine (Seroquel): an effective and well-tolerated atypical antipsychotic. Int J Psychiatry Clin Pract 1997;1:231–239
- Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32:215–228
- Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183–190
- Ghaemi SN, Katzow JJ, Desai SP, et al. Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 1998;59:426–429
- Wassef A, Watson D, Morrison P, et al. Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. J Clin Psychopharmacol 1989;9:45–48
- 72. Lyketsos CG. Neuropsychiatry. Psychosomatics 2000;41:1-4
- 73. Brady KT, Sonne SC, Roberts JM. Sertraline treatment of comorbid post-

traumatic stress disorder and alcohol dependence. Am J Psychiatry 1995; 56:502–505

- Kline NA, Dow BM, Brown SA, et al. Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder [letter]. Am J Psychiatry 1994;151:621
- Hagger C, Buckley P, Kenney JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702–712
- Rossi A, Mancini F, Stratta P, et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 1997;95:40–43
- Cook EH Jr, Rowlett R, Jaselskis C, et al. Fluoxetine treatment in children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992;31:739–745
- McDougle CJ, Brodkin ES, Naylor ST, et al. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998;18:62–66
- Neppe VJ. Integration of the evaluation and management of the transient closed head injury patient: some directions. In: Varney N, Roberts R, eds. Evaluation and Treatment of Mild Traumatic Brain Injury. Mahwah, NJ: Erlbaum and Associates; 1999;421–450
- Heard HL, Linehan MM. Dialectical behavior therapy: an integrative approach to the treatment of borderline personality disorder. J Psychother Integration 1994;4:55–82
- Linehan MM, Schmidt H. The dialectics of effective treatment of borderline personality disorder. In: O'Donohue WO, Krasner L, eds. Theories in Behavior Therapy: Exploring Behavior Change. Washington, DC: American Psychological Association; 1995
- Young CR, Longhurst JG, Bowers MG Jr, et al. The expanding indications for clozapine. Clin Psychopharmacol 1997;5:216–234
- Bacher NM, Kaup BA. Combining risperidone with standard neuroleptics for refractory schizophrenic patients [letter]. Am J Psychiatry 1996;153: 137
- Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry 1998;59(suppl 3):8–14
- Hector RI. The use of clozapine in the treatment of aggressive schizophrenia. Can J Psychiatry 1998;43:466–472
- Chengappa KNR, Ebeling T, Kang JS, et al. Clozapine reduces severe selfmutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 1999;60:477–484
- Daniel DG, Whitcomb SR. Treatment of the refractory schizophrenic patient. Presented at the closed Janssen Pharmaceutica symposium "Clinical Outcomes in the Treatment of Schizophrenia"; April 12, 1996; New Orleans, La
- Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–796
- Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992;160(suppl 17):41–45
- Armstrong SC, Stephans JR. Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage [letter]. J Clin Psychiatry 1997;58:499
- Tatro D, ed. Drug Interactions Facts and Comparisons. St. Louis, Mo: JB Lippincott; 1998
- Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59(suppl 3):3–7
- Wiebe EJ. Weight gain with clozapine treatment [letter]. Can J Psychiatry 1993;38:70
- Fertig MK, Brooks VG, Shelton PS, et al. Hyperglycemia associated with olanzapine [letter]. J Clin Psychiatry 1998;59:687–689
- Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus [letter]. Am J Psychiatry 1999;156:1471
- Reinstein MJ, Sirotovskaya LA, Jones LE, et al. Effect of clozapinequetiapine combination therapy on weight and glycaemic control. Clin Drug Invest 1999;18:99–104
- 97. VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level

ranges. Am J Psychiatry 1996;153:1579-1584

- Chouinard G, Jones BJ, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25–40. Correction 1993;13:149
- Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825–835
- Levinson DF, Umapathy C, Mushtaq M. Treatment of schizoaffective disorder and schizophrenia and mood symptoms. Am J Psychiatry 1999; 156:1138–1148
- Cabras PL, Hardoy MJ, Hardoy MC, et al. Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. J Clin Psychiatry 1999;60:245–248
- Erfurth A, Walden J, Grunze H. Lamotrigine in the treatment of schizoaffective disorder. Neuropsychobiology 1998;38:204–205
- Keck PE Jr, McElroy SL, Strakowski SM. New developments in the pharmacologic treatment of schizoaffective disorder. J Clin Psychiatry 1996;57(suppl 9):41–48
- Siris SG. Management of depression in schizophrenia. Psychiatr Ann 2000;30:13–19
- Oyesanmi O, Kunkel EJ, Monti DA, et al. Hematologic side effects of psychotropics. Psychosomatics 1999;40:414–421
- Gerald M, ed. Drug interactions: phenytoin. American Hospital Formulary Service Drug Information 1999;28(16):2008
- Hare RD. The Hare PCL-R: some issues concerning its use and misuse. Leg Criminological Psychol 1988;3:101–122
- Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence (Cochrane Review). In: Cochrane Library [serial online]. 2000; issue 1
- Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are responders to clozapine. Biol Psychiatry 1997;15:522–523
- Takhar J. Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine. J Psychiatry Neurosci 1999;24: 248–249
- Hirschfeld RMA, Allen MH, McEvoy J, et al. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry 1999;60:815–818
- Cheng G. D₂ occupancy decides antipsychotic dosage. Clinical Psychiatric News Jan 2000;28:14
- Shon SP, Toprac MG, Crismon ML, et al. Strategies for implementing psychiatric medication algorithms in the public sector. J Pract Psychiatry Behav Health 1999;5:32–36
- Gilbert DA, Altshuler KZ, Rago WV, et al. Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 1998;59:345–351
- 115. Rush AJ, Crismon ML, Toprac MG, et al. Consensus guidelines in the treatment of major depressive disorder. J Clin Psychiatry 1998;59 (suppl 20):73–84
- Rush AG, Rago WV, Crismon ML, et al. Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. J Clin Psychiatry 1999;60:284–291
- 117. Beck NC, Menditto AA, Baldwin L, et al. Reduced frequency of aggressive behavior in forensic patients in a social learning program. Hosp Community Psychiatry 1991;42:750–752
- Paul GL, Menditto AA. Effectiveness of inpatient treatment programs for mentally ill adults in public psychiatric facilities. Appl Prev Psychol 1992;1:41–63
- Smith GR Jr, Fischer EP, Nordquist CR, et al. Implementing outcomes management systems in mental health settings. Psychiatr Serv 1997;48: 364–368
- Frisch MB. Quality of Life Inventory (revised). Minneapolis, Minn: National Computer Systems Incorporated; 1994
- Smith GR, Manderscheid RW, Flynn LM, et al. Principles for assessment of patient outcomes in mental health care. Psychiatr Serv 1997;48: 1033–1036
- Marder SR. Facilitating compliance with antipsychotic medication. J Clin Psychiatry 1998;59(suppl 3):21–25